Navidea Biopharmaceuticals (NAVB) 10-K 27 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 17, 2023	Jun. 30, 2022
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-35076
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1080091
Entity Address, Address Line One	4995 Bradenton Avenue, Suite 240
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017-3552
City Area Code	614
Local Phone Number	793-7500
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 14,273,755
Entity Common Stock, Shares Outstanding (in shares)		32,851,252
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	Hartford, CT
Entity Central Index Key	0000810509
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	NAVB
Security Exchange Name	NYSEAMER
Preferred Stock Purchase Rights [Member]
Document Information [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,995,860	$ 4,230,865
Receivables	630	92,992
Inventory, net	427,344	151,155
Prepaid expenses and other	780,110	908,273
Total current assets	3,203,944	5,383,285
Property and equipment	835,845	866,306
Less accumulated depreciation and amortization	700,498	745,816
Property and equipment, net	135,347	120,490
Right-of-use lease assets	107,243	448,940
Less accumulated amortization	86,943	320,725
Right-of-use lease assets, net	20,300	128,215
License agreements, patents and trademarks	1,215,604	953,424
Less accumulated amortization	215,363	167,773
License agreements, patents and trademarks, net	1,000,241	785,651
Other assets	11,774	227,192
Total assets	4,371,606	6,644,833
Current liabilities:
Accounts payable	2,122,538	1,421,317
Accrued liabilities and other	6,456,762	3,108,515
Notes payable, current	543,613	453,427
Lease liabilities, current	18,976	275,718
Deferred revenue, current	800,000	40,825
Total current liabilities	9,941,889	5,299,802
Lease liabilities, net of current portion	1,312	20,288
Note payable to related party, net of discount of $628,285	1,871,715	0
Deferred revenue	700,000	700,000
Total liabilities	12,514,916	6,020,090
Stockholders’ (deficit) equity:
Common stock; $.001 par value; 300,000,000 shares authorized; 32,687,666 and 30,279,922 shares issued and outstanding as of December 31, 2022 and 2021, respectively	223,684	221,277
Additional paid-in capital	379,343,124	370,459,705
Accumulated deficit	(388,002,649)	(370,787,610)
Total stockholders' deficit	(8,435,828)	(106,556)
Noncontrolling interest	292,518	731,299
Total Navidea stockholders’ (deficit) equity	(8,143,310)	624,743
Total liabilities and stockholders’ (deficit) equity	4,371,606	6,644,833
Non-Series Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	0
Series D Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	22
Series E Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock subscription	0	50
Series G Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	3	0
Series H Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	0
Series I Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	$ 10	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	32,687,666	30,279,922
Common stock, shares outstanding (in shares)	32,687,666	30,279,922
Non-Series Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	150,000	150,000
Preferred stock, shares issued (in shares)	0	22,077
Preferred stock, shares outstanding (in shares)	0	22,077
Series E Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000	50,000
Preferred stock, shares issued (in shares)	0	50,000
Preferred stock, shares outstanding (in shares)	0	50,000
Series G Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	3,260	3,260
Preferred stock, shares issued (in shares)	3,260
Preferred stock, shares outstanding (in shares)	3,260	0
Series H Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	75,000	75,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series I Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	35,000	35,000
Preferred stock, shares issued (in shares)	9,480	0
Preferred stock, shares outstanding (in shares)	9,480	0
Note Payable to Related Party [Member]
Note payable to related party, discount	$ 628,285

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Revenue:
Revenue from contract with customer		$ 14,645	$ 45,615
Grant and other revenue		51,007	485,898
Total revenue		65,652	531,513
Cost of revenue		1,941	0
Adjustments for expired and expiring inventory		183,006
Gross (loss) profit		(119,295)	531,513
Operating expenses:
Research and development		5,969,774	5,141,910
Selling, general and administrative		7,961,826	7,450,015
Total operating expenses		13,931,600	12,591,925
Loss from operations	[1]	(14,050,895)	(12,060,412)
Other (expense) income:
Interest expense, net		(1,098,322)	(6,361)
Gain on extinguishment of debt		0	366,000
Other, net		(27,939)	(14,115)
Total other (expense) income, net		(1,126,261)	345,524
Net loss before income taxes		(15,177,156)	(11,714,888)
Provision for income taxes		0	(16,043)
Net loss		(15,177,156)	(11,730,931)
Net loss attributable to noncontrolling interest		3	4
Net loss attributable to Navidea and subsidiaries		(15,177,153)	(11,730,927)
Deemed dividend on preferred stock exchanged for Units		(2,037,886)	0
Net loss attributable to common stockholders		$ (17,215,039)	$ (11,730,927)
Loss attributable to common stockholders per common share (basic and diluted) (in dollars per share)		$ (0.56)	$ (0.40)
Weighted average shares outstanding (in shares)		30,901,869	29,343,542
Royalty [Member]
Revenue:
Revenue from contract with customer		$ 14,645	$ 0
License [Member]
Revenue:
Revenue from contract with customer		$ 0	$ 45,615
[1]Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series E Preferred Stock [Member]	Preferred Stock [Member] Series F Preferred Stock [Member]	Preferred Stock [Member] Series I Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock Subscription [Member] Series D Preferred Stock [Member]	Preferred Stock Subscription [Member] Series E Preferred Stock [Member]	Preferred Stock Subscription [Member] Series F Preferred Stock [Member]	Preferred Stock Subscription [Member] Series I Preferred Stock [Member]	Preferred Stock Subscription [Member]	Preferred Stock Subscriptions Receivable [Member] Series D Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member] Series E Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member] Series F Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member] Series I Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member]	Common Stock [Member] Series D Preferred Stock [Member]	Common Stock [Member] Series E Preferred Stock [Member]	Common Stock [Member] Series F Preferred Stock [Member]	Common Stock [Member] Series I Preferred Stock [Member]	Common Stock [Member]	Common Stock Subscription [Member] Series D Preferred Stock [Member]	Common Stock Subscription [Member] Series E Preferred Stock [Member]	Common Stock Subscription [Member] Series F Preferred Stock [Member]	Common Stock Subscription [Member] Series I Preferred Stock [Member]	Common Stock Subscription [Member]	Common Stock Subscriptions Receivable [Member] Series D Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member] Series E Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member] Series F Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member] Series I Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member]	Additional Paid-in Capital [Member] Series D Preferred Stock [Member]	Additional Paid-in Capital [Member] Series E Preferred Stock [Member]	Additional Paid-in Capital [Member] Series F Preferred Stock [Member]	Additional Paid-in Capital [Member] Series I Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Series D Preferred Stock [Member]	Retained Earnings [Member] Series E Preferred Stock [Member]	Retained Earnings [Member] Series F Preferred Stock [Member]	Retained Earnings [Member] Series I Preferred Stock [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member] Series D Preferred Stock [Member]	Noncontrolling Interest [Member] Series E Preferred Stock [Member]	Noncontrolling Interest [Member] Series F Preferred Stock [Member]	Noncontrolling Interest [Member] Series I Preferred Stock [Member]	Noncontrolling Interest [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Series F Preferred Stock [Member]	Series I Preferred Stock [Member]	Total
Balance, January 1, 2021 (in shares) at Dec. 31, 2020					0					132,250										27,149,691					995,000
Balance, January 1, 2021 at Dec. 31, 2020					$ 0					$ 132					$ (10,300,000)					$ 218,146					$ 995					$ (4,975,000)					$ 375,428,014					$ (359,056,683)					$ 731,303					$ 2,046,907
Issued restricted stock (in shares)					0					0										105,000					0
Issued restricted stock					$ 0					$ 0					0					$ 106					$ 0					0					0					0					0					106
Issued stock to 401(k) plan (in shares)					0					0										30,018					0
Issued stock to 401(k) plan					$ 0					$ 0					0					$ 30					$ 0					0					76,816					0					0					76,846
Issued stock (in shares)	76,827	50,000				(76,827)	0									0	0				0	0
Issued stock	$ 77	$ 50				$ (76)	$ 0				$ 2,550,000	$ 0				$ 0	$ 0				$ 0	$ 0				$ 0	$ 0				$ 0	$ 4,929,988				$ 0	$ 0				$ 0	$ 0				$ 2,550,001	$ 4,930,038
Issued stock upon conversion (in shares)	(54,750)					0										2,951,509					0
Issued stock upon conversion	$ (55)					$ 0					0					$ 2,951					$ 0					0					(2,896)					0					0					0
Stock subscribed (in shares)	0				0	(55,423)				0						0				0	0				(995,000)
Stock subscribed	$ 0				$ 0	$ (56)				$ 0	7,750,000				0	$ 0				$ 0	$ 0				$ (995)	0				4,975,000	(5,542,245)				(4,974,005)	0				0	0				0	2,207,699				$ 0
Issued stock upon stock option exercise (in shares)					0					0										4,000					0																									4,000
Issued stock upon stock option exercise					$ 0					$ 0					0					$ 4					$ 0					0					4,236					0					0					$ 4,240
Issued stock in lieu of cash for payment of director fees (in shares)					0					0										53,819					0
Issued stock in lieu of cash for payment of director fees					$ 0					$ 0					0					$ 54					$ 0					0					85,881					0					0					85,935
Cancelled stock to pay employee tax obligations (in shares)					0					0										(14,115)					0
Cancelled stock to pay employee tax obligations					$ 0					$ 0					0					$ (14)					$ 0					0					(17,346)					0					0					(17,360)
Stock compensation expense					0					0					0					0					0					0					471,262					0					0					471,262
Net loss					$ 0					$ 0					0					$ 0					$ 0					0					0					(11,730,927)					(4)					$ (11,730,931)
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)																																																		30,018
Stock Issued During Period, Value, Employee Benefit Plan																																																		$ 76,846
Balance, December 31, 2021 (in shares) at Dec. 31, 2021					72,077					0										30,279,922					0
Balance, December 31, 2021 at Dec. 31, 2021					$ 72					$ 0					0					$ 221,277					$ 0					0					370,459,705					(370,787,610)					731,299					624,743
Issued restricted stock (in shares)					0					0										30,000					0
Issued restricted stock					$ 0					$ 0					0					$ 30					$ 0					0					0					0					0					30
Issued stock to 401(k) plan (in shares)					0					0										44,782					0
Issued stock to 401(k) plan					$ 0					$ 0					0					$ 45					$ 0					0					24,802					0					0					24,847
Issued stock (in shares)				10,423	0				0	0									0	70,500				0	0
Issued stock				$ 10	$ 0				$ 0	$ 0				$ 0	0				$ 0	$ 71				$ 0	$ 0				$ 0	0				$ 5,174,589	19,669				$ 0	0				$ 0	0				$ 5,174,599	$ 19,740
Issued stock upon conversion (in shares)				(943)					0										2,095,490					0
Issued stock upon conversion				$ (1)					$ 0					$ 0					$ 2,095					$ 0					$ 0					$ (2,094)					$ 0					$ 0					$ 0
Issued stock upon stock option exercise (in shares)																																																		0
Issued stock in lieu of cash for payment of director fees (in shares)					0					0										51,373					0
Issued stock in lieu of cash for payment of director fees					$ 0					$ 0					0					$ 51					$ 0					0					22,515					0					0					$ 22,566
Stock compensation expense					0					0					0					0					0					0					301,351					0					0					301,351
Net loss					0					0					0					$ 0					0					0					0					(15,177,153)					(3)					$ (15,177,156)
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)																				53,238																														53,238
Stock Issued During Period, Value, Employee Benefit Plan																				$ 53															44,667															$ 44,720
MT Preferred Stock reacquired due to Platinum settlement					0					0					0					0					0					0					438,778					0					(438,778)					0
Stock exchanged (in shares)	(23,817)		(45,000)			0		0								0		0			0		0
Stock exchanged	$ (23)		$ (45)			$ 0		$ 0			$ 0		$ 0			$ 0		$ 0			$ 0		$ 0			$ 0		$ 0			$ 23		$ 821,295			$ 0		$ 0			$ 0		$ 0			$ 0		$ 821,250		821,250
Deemed dividend on Series D and Series F Preferred Stock exchanged for Units in Rights Offering					$ 0					$ 0					0					$ 0					$ 0					0					2,037,886					(2,037,886)					0					0
Issued stock pursuant to warrant exercise (in shares)					0					0										62,361					0
Issued stock pursuant to warrant exercise					$ 0					$ 0					$ 0					$ 62					$ 0					0					(62)					0					0					0
Balance, December 31, 2021 (in shares) at Dec. 31, 2022					12,740															32,687,666
Balance, December 31, 2021 at Dec. 31, 2022					$ 13					$ 0										$ 223,684					$ 0					$ 0					$ 379,343,124					$ (388,002,649)					$ 292,518					$ (8,143,310)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (15,177,156)	$ (11,730,931)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	48,229	36,803
Amortization of license agreements, patents and trademarks	47,590	40,151
Loss on disposal and abandonment of patents and equipment	65,082	98,733
Adjustments for expired and expiring inventory	183,006	0
Amortization of debt discount and issuance costs	207,591	0
Non-cash lease expense	107,915	121,880
Stock compensation expense	301,351	471,262
Gain on extinguishment of debt	0	(366,000)
Value of stock issued to 401(k) plan for employer matching contributions	44,720	76,846
Value of stock issued in payment of employee bonuses	24,847	0
Value of stock issued in payment of director fees	22,566	85,935
Value of stock issued under long term incentive plan	19,740	0
Changes in operating assets and liabilities:
Receivables	92,363	(30,675)
Inventory	(459,195)	18,643
Prepaid expenses and other assets	951,856	358,203
Accounts payable	701,221	259,600
Accrued and other liabilities	3,348,247	622,738
Lease liabilities	(275,718)	(294,951)
Deferred revenue	759,175	13,608
Net cash used in operating activities	(8,986,570)	(10,218,155)
Cash flows from investing activities:
Payments for purchases of equipment	(63,086)	(25,218)
Patent and trademark costs	(327,263)	(304,206)
Net cash used in investing activities	(390,349)	(329,424)
Cash flows from financing activities:
Proceeds from issuance of preferred stock and warrants, including collection of stock subscriptions	6,173,000	12,682,700
Proceeds from issuance of common stock	30	4,346
Payment of tax withholdings related to stock-based compensation	0	(17,360)
Proceeds from note payable	2,500,000	0
Payment of debt issuance costs	(14,626)	0
Principal payments on notes payable	(518,089)	(491,775)
Net cash provided by financing activities	7,141,914	12,107,949
Net increase in cash and cash equivalents	(2,235,005)	1,560,370
Cash and cash equivalents, beginning of period	4,230,865	2,670,495
Cash and cash equivalents, end of period	1,995,860	4,230,865
Preferred Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of preferred stock issuance costs	$ (998,401)	$ (69,962)

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Organization and Summary of Significant Accounting Policies a. Organization and Nature of Operations: Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Other than Tc99m tilmanocept, which the Company has a license to distribute outside of Canada, Mexico and the United States, none of the Company’s drug product candidates have been approved for sale in any market. In July 2011, we established a British business unit, Navidea Biopharmaceuticals Limited (“Navidea UK”), to address European and international development and commercialization needs for our technologies, including Tc99m tilmanocept. Navidea owns 100% of the outstanding shares of Navidea UK. In January 2015, Macrophage Therapeutics, Inc. (“MT”) was formed specifically to explore immuno-therapeutic applications for the Manocept platform. Navidea owns 99.96% of the outstanding shares of MT. In June 2020, in anticipation of the United Kingdom’s separation from the European Union (“Brexit”), we established an Irish entity, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”). Following Brexit, Navidea Europe allows us to continue to develop and commercialize our technologies within the European Union (“EU”) as well as internationally. Navidea owns 100% of the outstanding shares of Navidea Europe. b. Principles of Consolidation: c. Use of Estimates: d. Revenue Recognition: We also earn revenue from product sales to end customers, primarily in Europe. Revenue from product sales is generally recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Our customers have no right to return products purchased in the ordinary course of business, however, we may allow returns in certain circumstances based on specific agreements. In addition, we earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development (“R&D”) costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. e. Stock-Based Compensation: Stock options granted under the 2002 Plan and the 2014 Plan generally vest on an annual basis over one four ten Stock-based payments to employees and directors, including grants of stock options and restricted stock, are recognized in the statements of operations based on their estimated fair values on the date of grant, subject to an estimated forfeiture rate. The fair value of each option award with time-based vesting provisions is estimated on the date of grant using the Black-Scholes option pricing model. The determination of fair value using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option behaviors. The fair value of each option award with market-based vesting provisions is estimated on the date of grant using a Monte Carlo simulation. The determination of fair value using a Monte Carlo simulation is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option behaviors. Expected volatilities are based on the Company’s historical volatility, which management believes represents the most accurate basis for estimating expected future volatility under the current circumstances. Navidea uses historical data to estimate forfeiture rates. The expected term of stock options granted is based on the vesting period and the contractual life of the options. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant. The assumptions used to calculate the fair value of stock option awards granted during the years ended December 31, 2022 and 2021 are noted in the following table. 2022 2021 Expected volatility 92% - 100% 90% - 102% Weighted-average volatility 94% 95% Expected forfeiture rate 8.4% - 8.9% 5.2% - 9.0% Expected term (in years) 6.2 - 6.3 5.5 - 6.2 Risk-free rate 1.7% - 2.5% 0.6% - 1.4% Expected dividends — — The portion of the fair value of stock-based awards that is ultimately expected to vest is recognized as compensation expense over either (1) the requisite service period or (2) the estimated performance period. Restricted stock awards are valued based on the closing stock price on the date of grant and amortized ratably over the estimated life of the award. Restricted stock may vest based on the passage of time, or upon occurrence of a specific event or achievement of goals as defined in the grant agreements. In such cases, we record compensation expense related to grants of restricted stock based on management’s estimates of the probable dates of the vesting events. Stock-based awards that do not vest because the requisite service period is not met prior to termination result in reversal of previously recognized compensation cost. See Note 4. f. Net Loss Per Share: g. Research and Development Costs: h. Receivables: i. Inventory: j. Intangible Assets: k. Leases: l. Contingent Liabilities: Contingencies Following the ruling by the Texas Court in August 2022, the Company recorded $2.6 million in legal fees pursuant to the CRG judgment during the third quarter of 2022. As of December 31, 2022, the Company has accrued $3,385,429 of legal fees and interest pursuant to the CRG judgment. We have concluded that a loss from the Goldberg case is not determinable or reasonably estimable and, therefore, a liability has not m. Debt: Debt n. Preferred Stock: Distinguishing Liabilities from Equity Derivatives and Hedging Debt Presentation in Financial Statements of Redeemable Preferred Stocks Accounting for Convertible Instruments and Contracts in an Entity s Own Equity o. Preferred Stock Issued with Warrants: Distinguishing Liabilities from Equity Derivatives and Hedging Presentation in Financial Statements of Redeemable Preferred Stocks i. Series I Preferred Stock: ii. Warrants: p. Income Taxes: Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no q. Recently Adopted Accounting Standards: Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options In November 2021, the FASB issued ASU No. 2021-10, Disclosures by Business Entities about Government Assistance r. Accounting Standards to be Adopted: Measurement of Credit Losses on Financial Instruments

Note 2 - Liquidity

Note 2 - Liquidity	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity The Company was engaged in litigation with Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Partners Capital Opportunity Fund, Platinum Partners Liquid Opportunity Master Fund L.P., Platinum Liquid Opportunity Management (NY) LLC, and Montsant Partners LLC (collectively, “Platinum”). The Platinum lawsuit was settled and dismissed in January 2022. In addition, the Company is engaged in ongoing litigation with our former President and Chief Executive Officer, Dr. Michael Goldberg. The Company is also engaged in ongoing litigation with CRG. On August 30, 2022, the District Court of Harris County, Texas (the “Texas Court”) made an oral ruling from the bench at the conclusion of the trial, awarding CRG approximately $2.6 million in attorney’s fees on their breach of contract claims against Navidea and MT. A formal written final judgment was entered by the Texas Court on August 31, 2022, however, the written judgment did not identify the basis and reasoning in support of the decision. On September 9, 2022, Navidea filed a request for findings of fact and conclusions of law, asking that the Texas Court state in writing the facts found by the Court and the Court’s conclusions of law. On October 11, 2022, the Texas Court filed their findings of fact and conclusions of law, which includes conclusions of law that the amounts due are subject to an interest rate of 18% per annum. The Company has objected to many of the findings of fact and conclusions of law and to any attempt to amend the final judgment as being untimely. The Texas Court’s judgment remains unchanged. The Company has appealed the Texas Court’s judgment to the Fourteenth Court of Appeals of Texas. As of December 31, 2022, the Company has accrued $3,385,429 of legal fees and interest pursuant to the Texas Court’s ruling. See Note 12. On April 10, 2022, the Company entered into a Stock Exchange and Loan Agreement (the “Stock Exchange Agreement”) with John K. Scott, Jr., the current Vice Chairman of our Board of Directors, pursuant to which Mr. Scott agreed to make a loan to the Company in the principal amount of up to $2.5 million, of which $1.5 million was funded on the closing date and $1.0 million was funded on July 1, 2022. The outstanding balance of the Bridge Note bears interest at a rate of 8% per annum, with payments of interest only to be made monthly over a period of two years. All outstanding principal, accrued and unpaid interest under the Bridge Note is due and payable on the second anniversary of the Stock Exchange Agreement. The Company’s obligations under the Bridge Note are secured by a first priority security interest in all of the Company’s assets and personal property pursuant to a Security Agreement. See Note 10. On August 30, 2022, the Company closed on an offering to its stockholders and certain warrant holders as of August 3, 2022 of the right to purchase up to 35,000 units (“Units”) at a subscription price of $1,000 per Unit (the “Rights Offering”). The Rights Offering resulted in the sale of 10,423 Units for aggregate gross proceeds of $6,173,000 to the Company. Of the total 10,423 Units sold, 4,250 Units were sold in exchange for and the surrender of outstanding shares of our Series D and Series F Preferred Stock. Each Unit consisted of one share of Series I Preferred Stock which is convertible into 2,222 shares of Common Stock and one warrant to purchase an additional 2,222 shares of our Common Stock at $0.45 per share (“Warrant”). If exercised, additional gross proceeds of up to $11.6 million may be received through the exercise of Warrants issued in the Rights Offering. The Warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $0.50 per share. Net proceeds after deducting fees and expenses of $998,401 related to the Rights Offering will be used to fund our pivotal Phase 3 clinical trial for rheumatoid arthritis, obtaining regulatory approvals, working capital, and for general corporate purposes. See Note 13. The Company has previously entered into an API Development Funding and Access Agreement (“API Development Agreement”) with a strategic partner for assistance with the development and supply of the active pharmaceutical ingredient (“API”) used to manufacture Lymphoseek (technetium Tc 99m tilmanocept) that is sold by the Company in countries other than the United States, Canada and Mexico. Under the API Development Agreement, among other things, the strategic partner agreed to reimburse the Company for up to a total of $1.85 million of the Company’s out-of-pocket costs associated with such development, in two installments, subject to specified commercial and regulatory milestones. On August 11, 2022, the Company received the first installment in the amount of $800,000, which the strategic partner has the right to claw back if the Company does not satisfy certain commercial and regulatory milestones on or before March 31, 2023. The strategic partner is obligated, subject to certain conditions, to pay the remaining reimbursement amount upon the later of July 1, 2023 or satisfaction of specified commercial and regulatory milestones. We do not believe there has been a significant impact to the Company’s clinical development and regulatory timelines resulting from the ongoing COVID-19 global pandemic. However, the COVID-19 outbreak delayed enrollment in our NAV3-32 clinical study in the United Kingdom (“UK”) due to national COVID-19-related shutdowns. In addition, the regulatory approval process in India was delayed by the impact of COVID-19 in that country. The current conflict between Ukraine and Russia has created volatility in the global capital markets and is continuing to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties who operate in Europe on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any debt or equity financing more difficult to obtain, more costly or more dilutive. The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The Company also continues working to establish new sources of funding, including potential equity and/or debt financings, collaborations and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, management believes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the filing of this Annual Report on Form 10-K.

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue from Contracts with Customers and Other Revenue Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two primary types of drug products: (i) diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of our Manocept platform, and (ii) therapeutic development programs, including all therapeutic applications of our Manocept platform. Tc99m tilmanocept, which the Company has a license to distribute outside of Canada, Mexico and the United States, is the only one of the Company’s drug product candidates that has been approved for sale in any market. Tc99 tilmanocept has only been approved for sale in the European Union (“EU”), the UK, India and Australia. We earn revenue from product sales to end customers, primarily in Europe. Revenue from product sales is generally recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Our customers have no right to return products purchased in the ordinary course of business, however, we may allow returns in certain circumstances based on specific agreements. Normal payment terms generally range from 30 to 90 days from invoice date, in accordance with each contract or purchase order. The Company also recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 to 90 days following milestone achievement or royalty invoice, in accordance with each contract. Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m tilmanocept has been approved by the regulatory authorities and product sales are authorized to commence in each of those countries. The Company received regulatory approval for Tc99m tilmanocept in India in late March 2022, however certain additional approvals, such as an import license and authorization to use an alternative manufacturer, must be obtained prior to commercial sales launch in India. It is not possible to determine with any degree of certainty whether or when regulatory approval for this product will be achieved in China, if at all. In addition, since sales of Tc99m tilmanocept have not yet begun in India or China, there is no basis for estimating whether, to what degree, or the rate at which the product will be accepted and utilized in these markets. Therefore, it is not possible to determine with any degree of certainty the expected sales in future periods in those countries. As such, the Company intends to recognize revenue from up-front and milestone payments on a straight-line basis beginning at the time of commercial sales launch in each country through the end of the initial term of each agreement. The initial term of each agreement is eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not include amounts collected on behalf of third parties (e.g., sales taxes). To determine the transaction price of a contract, the Company considers the terms of the contract. For the purpose of determining transaction prices, the Company assumes that the goods or services will be transferred to the customer as promised in accordance with existing contracts and that the contracts will not be cancelled, renewed, or modified. When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no direct influence. For example, regulatory approval or product sales volume milestones are contingent upon the achievement of those milestones by the distributor. Additionally, the prices charged to end users of Tc99m tilmanocept, upon which royalty payments are based in India and China, are set by the distributor in each of those countries. The milestone payments have a binary outcome (that is, the Company will either receive all or none of each milestone payment) and can be estimated using the most-likely-amount method. Taking into account the constraint on variable consideration, the Company has assessed the likelihood of achieving the non-sales-based milestone payments in our current contracts and has determined that it is probable the milestones will be achieved and the Company will receive the consideration. Accordingly, it is probable that including those payments in the transaction price will not result in a significant revenue reversal when the contingency is resolved. Therefore, the amount of the non-sales-based milestone payments is included in the transaction price. Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. This conclusion is based on the fact that Tc99m tilmanocept is early in the commercial launch process in Europe and Australia, and sales have not yet begun in India or China, therefore there is currently no basis for estimating whether, to what degree, or the rate at which the product will be accepted and utilized in these markets. Similarly, we currently have no basis for estimating whether sales-based milestones will ever be achieved. Accordingly, the Company recognizes revenue from royalties when the related sales occur and from sales-based milestones when they are achieved. Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not estimate expected refunds nor do we adjust revenue downward. The Company will evaluate and update the estimated transaction prices of its contracts with customers at the end of each reporting period. During the years ended December 31, 2022 and 2021, the Company recognized revenue from contracts with customers of $14,645 and $45,615, respectively. During the years ended December 31, 2022 and 2021, the Company did not The following table disaggregates the Company’s revenue from contracts with customers for the years ended December 31, 2022 and 2021. Years Ended December 31, 2022 2021 Sales revenue: Tc99m tilmanocept – Europe $ 14,035 $ — Tc99m tilmanocept – Australia 610 — Total sales revenue 14,645 — License revenue: Tc99m tilmanocept - Europe $ — $ 45,615 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers. Status of Regulatory Approval. Through December 31, 2022, the Company has not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets during the years ended December 31, 2022 and 2021. Years Ended December 31, 2022 2021 Total deferred revenue related to contracts with customers, beginning of period $ 700,000 $ 700,000 Deferred revenue related to milestones achieved 100,000 — Deferred revenue related to milestones achieved, written off due to contract renegotiations (100,000 ) — Total deferred revenue related to contracts with customers, end of period $ 700,000 $ 700,000 The Company had sales revenue receivable of $610 and $0 outstanding as of December 31, 2022 and 2021, respectively. The Company had license revenue receivable of $0 and $1,021 outstanding as of December 31, 2022 and 2021, respectively. In addition to revenue from contracts with customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not have a vendor-customer relationship with the NIH and the grant awards are outside the scope of the revenue recognition standard. Accordingly, the revenue recognition standard need not be applied to the NIH grants. During the years ended December 31, 2022 and 2021, the Company recognized grant revenue of $51,007 and $87,898, respectively. Finally, we expect to recognize revenue from a strategic development partner up to a total of $1.85 million under the terms of the API Development Agreement. Based on the nature of the Company’s operations and the terms of the API Development Agreement, Navidea does not have a vendor-customer relationship with the strategic partner and amounts received under the API Development Agreement are outside the scope of the revenue recognition standard. Accordingly, the revenue recognition standard need not be applied to the API Development Agreement. On August 11, 2022, the Company received the first installment in the amount of $800,000, which the strategic partner has the right to claw back if the Company does not satisfy certain commercial and regulatory milestones on or before March 31, 2023. The Company recorded the first installment as deferred revenue, current on its consolidated balance sheets.

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	4. Stock-Based Compensation For the years ended December 31, 2022 and 2021, our total stock-based compensation expense, which includes reversals of expense and incremental expense for certain modified, forfeited or cancelled awards, was $301,351 and $471,262, respectively. We have not On November 23, 2021, our former Chief Executive Officer, Chief Operating Officer and Chief Financial Officer, Jed A. Latkin, signed a Separation Agreement and General Release (the “Separation Agreement”) in connection with his resignation from those positions and as a director on October 24, 2021 (the “Separation Date”). Pursuant to the Separation Agreement, among other things, the Company agreed to provide Mr. Latkin with certain separation benefits, commencing on the “Effective Date,” defined as the eighth day after Mr. Latkin signed, without revoking, the Separation Agreement. On the Effective Date, each of Mr. Latkin’s unvested stock options vested, and all of his vested stock options (covering 69,918 shares) and previously unvested options (covering 333,332 shares) may be exercised by Mr. Latkin on or before the earlier of the fifth A summary of the status of our stock options as of December 31, 2022, and changes during the year then ended, is presented below. Year Ended December 31, 2022 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2022 919,790 $ 5.67 Granted 12,500 0.83 Canceled and forfeited (154,955 ) 2.37 Expired (74,530 ) 23.48 Outstanding, December 31, 2022 702,805 $ 4.42 5.5 $ — Exercisable, December 31, 2022 537,390 $ 5.31 4.5 $ — The weighted average grant-date fair value of options granted in 2022 and 2021 was $0.65 and $1.46, respectively. During 2021, 4,000 stock options with an aggregate intrinsic value of $2,500 were exercised in exchange for issuance of 4,000 shares of our Common Stock, resulting in gross proceeds of $4,240. No stock options were exercised during 2022. The aggregate fair value of stock options vested during 2022 and 2021 was $0 and $122,402, respectively. A summary of the status of our unvested restricted stock as of December 31, 2022, and changes during the year then ended, is presented below. Year Ended December 31, 2022 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2022 95,000 $ 1.40 Granted 30,000 0.24 Vested (35,000 ) 1.45 Unvested, December 31, 2022 90,000 $ 0.99 During 2022 and 2021, 35,000 and 70,000 shares, respectively, of restricted stock vested with aggregate vesting date fair values of $13,440 and $112,680, respectively. During 2022 and 2021, 35,000 and 20,000 shares of restricted stock held by non-employee directors with aggregate fair values of $13,440 and $42,730, respectively, vested as scheduled according to the terms of the restricted stock agreements. As of December 31, 2022, there was $84,062 of total unrecognized compensation cost related to stock option and restricted stock awards, which we expect to recognize over remaining weighted average vesting terms of 1.5 years.

Note 5 - Loss Per Share

Note 5 - Loss Per Share	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	5. Loss Per Share Diluted loss per common share for the years ended December 31, 2022 and 2021 excludes the effects of 24,066,771 and 1,892,114 common share equivalents, respectively, since such inclusion would be anti-dilutive. The excluded shares consist of common shares issuable upon exercise of outstanding stock options and warrants. The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested stock awards are generally required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 90,000 and 95,000 shares of unvested restricted stock for the years ended December 31, 2022 and 2021, respectively, were excluded in determining basic and diluted loss per share because such inclusion would be anti-dilutive.

Note 6 - Receivables

Note 6 - Receivables	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	6. Receivables Receivables as of December 31, 2022 and 2021 consist of the following: 2022 2021 Sales revenue $ 610 $ — Related parties — 86,796 License revenue — 1,021 Grant revenue — 919 Other 20 4,256 Total stock subscriptions and other receivables $ 630 $ 92,992 As of December 31, 2022 and 2021, there was no

Note 7 - Inventory, Net

Note 7 - Inventory, Net	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	7. Inventory, Net The components of inventory, net as of December 31, 2022 and 2021 are presented in the following table: December 31, 2022 December 31, 2021 Materials $ 27,405 $ 50,000 Work in process 399,939 — Finished goods 131,804 101,155 Reserve for expiring finished goods (131,804 ) — Total inventory, net $ 427,344 $ 151,155 During 2022, we reserved $133,006 of finished goods inventory based on our expectation that this inventory would expire before it could be sold or used in clinical trials. Also during 2022, we wrote off $50,000 of expired materials inventory. These transactions were recorded in adjustments for expired and expiring inventory in the consolidated statements of operations. No such inventory adjustments were recorded during 2021. During 2022 and 2021, we utilized $79,582 and $27,750, respectively, of inventory for process development purposes. Also during 2022 and 2021, we allocated $103,955 and $0, respectively, of inventory for use in clinical trials. These transactions were recorded in research and development expense in the consolidated statement of operations.

Note 8 - Property and Equipment

Note 8 - Property and Equipment	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	8. Property and Equipment The major classes of property and equipment are presented in the following table: Useful Life (in years) 2022 2021 Purchased software 3 $ 320,435 $ 320,435 Production machinery and equipment 5 175,460 214,356 Other machinery and equipment, primarily computers and research equipment 3 – 5 311,973 304,492 Leasehold improvements* Term of Lease 23,511 23,511 Furniture and fixtures 7 4,466 3,512 Total property and equipment $ 835,845 $ 866,306 * We amortize leasehold improvements over the term of the lease, which in all cases is shorter than the estimated useful life of the asset. During 2022 and 2021, we recorded $48,229 and $36,803, respectively, of depreciation and amortization related to property and equipment.

Note 9 - Accounts Payable, Accr

Note 9 - Accounts Payable, Accrued Liabilities and Other	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	9. Accounts Payable, Accrued Liabilities and Other Accounts payable as of December 31, 2022 and 2021 includes an aggregate of $318,527 and $57,099, respectively, due to related parties for director fees. Accrued liabilities and other as of December 31, 2022 and 2021 includes an aggregate of $811,554 and $1,194,719, respectively, due to related parties for accrued separation costs, bonuses, benefits and director fees. The Company pays director fees in both cash and stock. The cash portion of director fees due is included in accounts payable and the stock portion is included in accrued liabilities and other in the consolidated balance sheet as of December 31, 2022 and 2021. Certain directors have elected to defer receipt of cash and stock for director fees until the Company raises sufficient additional capital. Under our license agreements with the University of California, San Diego (“UCSD”), we have exclusive world-wide rights to all diagnostic and therapeutic uses of tilmanocept, other than Tc99m tilmanocept used in lymphatic mapping in the United States, Canada and Mexico which rights are licensed to Cardinal Health 414. The UCSD license agreements include obligations for payments related to license fees, milestones, and royalties. As of December 31, 2022, the Company has accrued approximately $1.5 million related to the UCSD license agreements for which we have not yet been invoiced. Of this amount, approximately $104,000 is included in accounts payable and $1.4 million is included in accrued expenses and other in the consolidated balance sheets. See Note 19(a). Accrued liabilities and other as of December 31, 2022 and 2021 are presented in the following table: 2022 2021 Contracted services $ 5,667,105 $ 1,913,756 Compensation 788,036 1,194,719 Other 1,621 — Total accrued liabilities and other $ 6,456,762 $ 3,108,515

Note 10 - Notes Payable

Note 10 - Notes Payable	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	10. Notes Payable Bridge Note from John K. Scott, Jr. On April 10, 2022, the Company entered into a Stock Exchange Agreement with John K. Scott, Jr., pursuant to which Mr. Scott agreed to make a loan to the Company in the principal amount of up to $2.5 million, of which $1.5 million was funded on the closing date and $1.0 million was funded on July 1, 2022. The outstanding balance of the loan, which is evidenced by a Bridge Note, bears interest at a rate of 8% per annum, with payments of interest only to be made monthly over a period of two years. All outstanding principal and accrued and unpaid interest under the Bridge Note is due and payable on the second anniversary of the Stock Exchange Agreement. The Company’s obligations under the Bridge Note are secured by a first priority security interest in all of the Company’s assets and personal property pursuant to a Security Agreement. See Note 13. As consideration and partial inducement for Mr. Scott to enter into the Bridge Note, the Company exchanged all 50,000 shares of Mr. Scott’s Series E Preferred Stock for 1,740 shares of Series F Preferred Stock and 3,260 shares of Series G Preferred Stock. In accordance with current accounting guidance, the Company recorded a debt discount of $835,876 including $821,250 related to the difference in the value of Mr. Scott’s Series E Preferred Stock and the Series F and Series G Preferred Stock and $14,626 of debt issuance costs. The debt discount is being amortized as non-cash interest expense using the effective interest method over the term of the Bridge Note. The balance of the debt discount was $628,285 as of December 31, 2022. Interest expense related to the Bridge Note totaled $334,592 during the year ended December 31, 2022. The principal balance of the Bridge Note was $2.5 million as of December 31, 2022. IPFS Corporation In November 2020, we prepaid $442,041 of insurance premiums through the issuance of a note payable to IPFS Corporation (“IPFS”) with an interest rate of 3.5%. The note was payable in seven five Interest expense related to the IPFS notes payable totaled $4,126 and $5,938 during the years ended December 31, 2022 and 2021, respectively. The balance of the IPFS note was $453,427 as of December 31, 2021, and was included in notes payable, current in the consolidated balance sheets. AFCO Premium Credit LLC In November 2022, we prepaid $608,275 of insurance premiums through the issuance of a note payable to AFCO Premium Credit LLC (“AFCO”) with an interest rate of 7.85%. The note is payable in nine monthly installments of $69,967, with the final payment due in August 2023. Interest expense related to the AFCO note payable totaled $5,306 during the year ended December 31, 2022. The balance of the AFCO note was $543,613 as of December 31, 2022, and was included in notes payable, current in the consolidated balance sheets. Paycheck Protection Program The CARES Act was enacted on March 27, 2020. Among the provisions contained in the CARES Act was the creation of the PPP that provides for SBA Section 7(a) loans for qualified small businesses. PPP Loan proceeds are available to be used to pay for payroll costs, including salaries, commissions, and similar compensation, group health care benefits, and paid leaves; rent; utilities; and interest on certain other outstanding debt. On May 18, 2020, the Lender funded the PPP Loan in the amount of $366,000. In accordance with the loan forgiveness requirements of the CARES Act, the Company used the proceeds from the PPP Loan primarily for payroll costs, rent and utilities. On February 23, 2021, the Lender notified the Company that the entire PPP Loan amount of $366,000 had been forgiven. The forgiveness was recorded as a gain on extinguishment of debt on the consolidated statement of operations. Summary During the years ended December 31, 2022 and 2021, we recorded interest expense of $344,024 and $5,938, respectively, related to our notes payable. Annual principal maturities of our notes payable are $543,613 and $2.5 million in 2023 and 2024, respectively.

Note 11 - Leases

Note 11 - Leases	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	11. Leases We currently lease approximately 5,000 square feet of office space at 4995 Bradenton Avenue, Dublin, Ohio, as our principal offices, at a monthly base rent of approximately $3,012. The current lease term expires in June 2023. In addition, we leased approximately 25,000 square feet of office space at 5600 Blazer Parkway, Dublin, Ohio, formerly our principal offices, at a monthly base rent of $28,149 in 2022. The lease term expired in October 2022 with an option to extend for an additional five years. The Company did not renew this lease. In June 2017, the Company executed a sublease arrangement for the Blazer Parkway space, providing for monthly sublease payments to Navidea of $39,124 through October 2022. We currently lease office equipment at a monthly payment of $136, expiring in October 2024. We also leased a vehicle at a monthly payment of $287, which expired in September 2021. Total operating lease expense was $123,309 and $171,818 for the years ended December 31, 2022 and 2021, respectively. Total operating lease expense for the year ended December 31, 2022 reflected receipt of one more payment from our sublessee than was originally anticipated at sublease inception. The additional receipt was recorded as a reduction of lease expense. Operating lease expense was recorded in selling, general and administrative expenses on our consolidated statements of operations. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2022. Maturity of Lease Liabilities Operating Lease Payments 2023 $ 19,699 2024 1,355 Total undiscounted operating lease payments 21,054 Less imputed interest 766 Present value of operating lease liabilities $ 20,288 Balance Sheet Classification Current lease liabilities $ 18,976 Noncurrent lease liabilities 1,312 Total operating lease liabilities $ 20,288 Other Information Weighted-average remaining lease term for operating leases (in years) 0.7 Weighted-average discount rate for operating leases 10.53 % Cash paid for amounts included in the present value of operating lease liabilities was $291,111 and $344,266 during the years ended December 31, 2022 and 2021, respectively, and is included in operating cash flows.

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. In accordance with ASC Topic 450, Contingencies CRG Litigation The Company has been engaged in ongoing litigation with CRG, in its capacity as a lender and as control agent for other affiliated lenders party to the CRG Loan Agreement (collectively, the “CRG Lenders”), in the Texas Court relating to CRG’s claims of default under the terms the CRG Loan Agreement. Following a trial in December 2017, the Texas Court ruled that the Company’s total obligation to CRG was in excess of $66.0 million, limited to $66.0 million under the Global Settlement Agreement (“GSA”) dated March 3, 2017. The Texas Court acknowledged only the $59.0 million payment made in March 2017, concluding that the Company owed CRG another $7.0 million, however the Texas Court did not expressly take the Company’s June 2016 payment of $4.1 million into account and awarded, as part of the $66.0 million, amounts that had already been paid as part of the $4.1 million. The Company believes that this $4.1 million should be credited against the $7.0 million and has appealed the Texas Court’s judgment. The Court of Appeals dismissed the Company’s appeal without reaching the merits due to a contractual waiver of appeal. In April 2018, CRG asserted claims against Navidea and MT for alleged breaches of the GSA and Loan Agreement entered into by Navidea arising from Navidea’s challenge to CRG’s drawing down on letters of credit in the full amount of $7,153,000. Navidea claimed such draw down resulted in an overpayment of approximately $4.2 million under the Loan Agreement. CRG also sought declaratory judgment relief that essentially mirrored their claims for affirmative relief, i.e., that the Company breached the GSA and indemnification provision of the Loan Agreement, and that CRG did not breach the GSA. On November 21, 2021, the Texas Court entered an interlocutory judgment declaring that CRG did not breach the GSA, but that Navidea did breach the GSA and the indemnification provision of the CRG Loan Agreement. In the interlocutory order, the Texas Court sua sponte awarded as damages reasonable attorneys' fees in an amount, if any, to be determined at trial. CRG made a claim of approximately $2.8 million in attorneys' fees they contend they are entitled to in connection with the alleged breaches of the agreements. Navidea contends CRG have received payments in excess of the amounts owed under the CRG Loan Agreement and are not entitled to an award of attorney’s fees under the GSA or Loan Agreement. On August 30, 2022, the Texas Court made an oral ruling from the bench at the conclusion of the trial, awarding CRG approximately $2.6 million in attorney’s fees on their breach of contract claims against Navidea and MT. A formal written final judgment was entered by the Texas Court on August 31, 2022, however, the written judgment did not identify the basis and reasoning in support of the decision. On September 9, 2022 Navidea filed a request for findings of fact and conclusions of law, asking that the Texas Court state in writing the facts found by the Court and the Court’s conclusions of law. On October 11, 2022, the Texas Court filed their findings of fact and conclusions of law, which includes conclusions of law that the amounts due are subject to an interest rate of 18% per annum. The Company has objected to many of the findings of fact and conclusions of law and to any attempt to amend the final judgment as being untimely. The Texas Court’s judgment remains unchanged. The Company has appealed the Texas Court’s judgment to the Fourteenth Court of Appeals of Texas. As of December 31, 2022, the Company has accrued approximately $3.4 million of legal fees and interest pursuant to the Texas Court’s ruling. The Company had also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”) related to Navidea’s claims that the CRG Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the CRG Lenders in connection with the GSA, pursuant to which Navidea agreed to pay up to $66.0 million to the CRG Lenders, as well as through actions and misrepresentations by CRG after the GSA was executed. The claims in that suit were for breach of contract, conversion and unjust enrichment against the CRG Lenders for their collection of more than $66.0 million, the maximum permitted under the GSA, and their double recovery of amounts paid as part of the $4.1 million paid in June 2016 and recovered again as part of the $66.0million. CRG’s double recovery and recovery of more than $66.0 million are due to CRG drawing the entire $7.1 million on the Cardinal Health 414 letter of credit. The CRG Lenders sought a Writ of Prohibition in the Ohio Supreme Court to prevent this case from moving forward, which was denied, and proceedings resumed in front of the Ohio Court. Following an unsuccessful mediation on May 7, 2019, Navidea moved for summary judgment on June 28, 2019. On November 27, 2019, the Ohio Court found that when CRG collected more than $66.0 million, they took an excess recovery and breached the GSA. The Ohio Court awarded approximately $4.3 million to Navidea, plus statutory interest from April 9, 2018, the date CRG drew on the Cardinal Health 414 letter of credit. The Ohio Court also found that there was no unjust enrichment or conversion by CRG since this was a matter of contract and only contract damages were appropriate. The decision was a final appealable order and terminated the case before the Ohio Court. On December 5, 2019, CRG filed a notice of appeal with Ohio’s 10th District Court of Appeals regarding the judgment in favor of Navidea. The briefing of the appeal concluded on March 27, 2020, and oral argument on the appeal was held on September 23, 2020. On March 16, 2021, Ohio’s 10th District Court of Appeals issued a decision which reversed the Ohio Court’s November 27, 2019 ruling that CRG breached the GSA and its award of $4.3 million plus statutory interest to Navidea. The Ohio Court of Appeals held that the Ohio Court did not have jurisdiction to adjudicate Navidea’s claims and therefore did not rule on the factual merits of Navidea’s claims regarding CRG’s recovery in excess of the contractually agreed maximum amount. The Ohio Supreme Court declined to hear the case so the Ohio litigation has concluded. Platinum Litigation In November 2017, Platinum-Montaur commenced an action against the Company in the Supreme Court of the State of New York, County of New York (the “New York Supreme Court”), seeking damages of approximately $1.9 million purportedly due as of March 3, 2017, plus interest accruing thereafter. The claims asserted were for breach of contract and unjust enrichment in connection with funds received by the Company under the Platinum Loan Agreement. The action was subsequently removed to the United States District Court for the Southern District of New York. On October 31, 2018, the District Court granted judgment for Navidea and dismissed all claims in the case. The District Court stated that Platinum-Montaur had no standing to assert any contractual interest in funds that might be due under the Platinum Loan Agreement. The District Court also disagreed with Platinum-Montaur’s claim of unjust enrichment on similar grounds and found that Platinum-Montaur lacked any sufficient personal stake to maintain claims against Navidea. The claims against Navidea were dismissed without prejudice on the grounds of lack of standing to pursue the claims asserted. On November 30, 2018, Platinum-Montaur filed a notice of appeal with the United States Court of Appeals for the Second Circuit (the “Second Circuit”) claiming that the District Court erred in dismissing Platinum-Montaur’s claims for breach of contract and unjust enrichment. On January 22, 2019, Platinum-Montaur filed its brief in the Second Circuit, asking the Second Circuit to reverse the District Court and remand the case to the District Court for further proceedings. The Second Circuit held oral argument in this matter on September 5, 2019. On November 25, 2019, the Second Circuit issued a decision which remanded the case to the District Court for further consideration of whether the District Court had jurisdiction over the case following removal from the New York Supreme Court. The Second Circuit did not address the merits of Platinum-Montaur’s allegations against Navidea. By agreement of the parties, the case was remanded from the District Court to the New York Supreme Court. Navidea filed a Motion to Dismiss on June 4, 2020, and on September 2, 2020, the New York Supreme Court granted the Motion to Dismiss. Platinum-Montaur filed a Notice of Appeal of the New York Supreme Court’s decision on September 23, 2020 and the appeal was docketed with the Appellate Department-First Division. Platinum-Montaur perfected an appeal of the judgment in favor of the Company on or about June 28, 2021. In February 2022, Platinum and the Company settled their dispute and Platinum’s lawsuit was dismissed. Goldberg Agreement and Litigation In August 2018, Dr. Goldberg resigned from his positions as an executive officer and a director of Navidea. In connection with Dr. Goldberg’s resignation, Navidea and Dr. Goldberg entered into an Agreement (the “Goldberg Agreement”) which set forth the terms of the separation from service. Among other things, the Goldberg Agreement provided that Dr. Goldberg would be entitled to 1,175,000 shares of our Common Stock, representing in part payment of accrued bonuses and payment of the balance of the Platinum debt. A portion of the 1,175,000 shares to be issued to Dr. Goldberg would be held in escrow for up to 18 months in order to reimburse Navidea in the event that Navidea is obligated to pay any portion of the Platinum debt to a party other than Dr. Goldberg. Further, the Goldberg Agreement provided that the Company’s subsidiary, MT, would redeem all of Dr. Goldberg’s preferred stock and issue to Dr. Goldberg super voting common stock equal to 5% of the outstanding shares of MT. In November 2018, the Company issued 925,000 shares of our Common Stock to Dr. Goldberg, 250,000 of which were placed in escrow in accordance with the Goldberg Agreement. On February 11, 2019, Dr. Goldberg represented to the MT Board that he had, without MT Board or shareholder approval, created a subsidiary of MT, transferred all of the assets of MT into the subsidiary, and then issued himself stock in the subsidiary. On February 19, 2019, Navidea notified MT that it was terminating the sublicense in accordance with its terms, effective March 1, 2019, due to MT’s insolvency. On February 20, 2019, the MT Board removed Dr. Goldberg as President and Chief Executive Officer of MT and from any other office of MT to which he may have been appointed or in which he was serving. Dr. Goldberg remains a member of the MT Board, together with John K. Scott, Jr. and Dr. Michael S. Rosol. Mr. Scott is also the Vice Chair of the Board of Directors of Navidea. On or about February 17, 2022, the Joint Official Liquidators and Foreign Representatives of PPVA executed the necessary paperwork to transfer its preferred stock in MT to Navidea. New York Litigation Involving Dr. Goldberg On February 20, 2019, Navidea filed a complaint against Dr. Goldberg in the United States District Court, Southern District of New York (the “District Court”), alleging breach of the Goldberg Agreement, as well as a breach of the covenant of good faith and fair dealing and to obtain a declaratory judgment that Navidea’s performance under the Goldberg Agreement is excused and that Navidea is entitled to terminate the Goldberg Agreement as a result of Dr. Goldberg’s actions. On April 26, 2019, Navidea filed an amended complaint against Dr. Goldberg which added a claim for breach of fiduciary duty seeking damages related to certain actions Dr. Goldberg took while CEO of Navidea. On June 13, 2019, Dr. Goldberg answered the amended complaint and asserted counterclaims against Navidea and third-party claims against MT for breach of the Goldberg Agreement, wrongful termination, injunctive relief, and quantum meruit. On December 26, 2019, the District Court ruled on several motions related to Navidea and MT and Dr. Goldberg that substantially limited the claims that Dr. Goldberg can pursue against Navidea and MT. Specifically, the District Court found that certain portions of Dr. Goldberg’s counterclaims against Navidea and third-party claims against MT failed to state a claim upon which relief can be granted. Additionally, the District Court ruled that actions taken by Navidea and MT, including reconstituting the MT board of directors, replacing Dr. Goldberg with Mr. Latkin as Chief Executive Officer of MT, terminating the sublicense between Navidea and MT, terminating certain research projects, and allowing MT intellectual property to revert back to Navidea, were not breaches of the Goldberg Agreement. The District Court also rejected Dr. Goldberg’s claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Michael Rice from MT’s Board of Directors, to invalidate all actions taken by the MT Board on or after November 29, 2018 (the date upon which Dr. Bruck and Mr. Rice were appointed by Navidea to the Board of MT), or to reinstate the terminated sublicense between Navidea and MT. In addition, the District Court found Navidea’s breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three years prior to the filing of the complaint to be time-barred and that Dr. Goldberg is entitled to an advancement of attorneys’ fees solely with respect to that claim. To avoid further litigation expenses, the Company agreed to indemnify Dr. Goldberg solely with respect to the breach of fiduciary duty claim. On January 31, 2020, Goldberg filed a motion for leave to amend his complaint to add back in claims for breach of contract, breach of the implied covenant of good faith and fair dealing, quantum meruit and injunctive relief. On April 1, 2020, the District Court denied Dr. Goldberg’s motion for leave to amend in its entirety. On January 27, 2020, Dr. Goldberg filed a motion seeking additional advancement from Navidea for fees in connection with the New York Action and the Delaware Action. Navidea opposed the motion and the District Court referred the matters to a Magistrate Judge. On July 9, 2020, the Magistrate Judge issued her Report and Recommendation which recommended that: (1) the District Court decline to exercise jurisdiction over Dr. Goldberg’s motion as it pertained to expenses and fees incurred in defense of the Delaware Action; (2) the District Court decline to award any fees to Dr. Goldberg for the breach of fiduciary duty without additional motion practice on the issue; (3) the District Court find that Dr. Goldberg is entitled to advancement of his expenses and fees reasonably incurred in the defense of the remainder of the New York action subject to Dr. Goldberg’s posting of an undertaking; and (4) establish a protocol by which Dr. Goldberg could establish the amounts due for advancement. On August 24, 2020, in connection with Dr. Goldberg’s motion for advancement, the District Court adopted the Magistrate Judge’s report and recommendation and found that while Dr. Goldberg was not being granted advancement of fees and expenses incurred in connection with either the Delaware Action or the assertion of third-party claims against MT, the Court ruled that Dr. Goldberg was entitled to advancement for the defense of the remaining claims asserted against him by Navidea in the New York action. The Court adopted a protocol by which additional motion practice will occur to determine the appropriate amount of fees to be advanced. Once that decision is made by the Magistrate Judge, subject to review by the District Court, Navidea will need to advance those fees to Dr. Goldberg conditioned upon Dr. Goldberg agreeing to pay those fees back to Navidea if it is determined that he is not entitled to indemnification. On May 27, 2021, the District Court ordered that: (1) Dr. Goldberg be awarded $14,955 for indemnification for his attorneys’ fees for his defense of the breach of fiduciary duty claim; (2) Dr. Goldberg be advanced $ 1,237.50 On August 6, 2021, the Company moved for reconsideration of its obligations to advance fees in light of the Delaware Court’s decision dated June 23, 2021 (described below). On October 14, 2021, the Magistrate Judge recommended that Navidea’s motion for reconsideration be denied. On March 7, 2022, the District Court adopted the Report and Recommendation in part and permitted Dr. Goldberg to seek advancement for his fees incurred in defense of his claims since September 1, 2020. On April 8, 2022, Dr. Goldberg submitted a fee application seeking advancement of $ 143,172.55 Fact discovery and expert discovery in the New York Action have been completed. The Company has moved to disqualify Dr. Goldberg’s damages expert and briefing in the District Court was submitted on April 1, 2022. On November 9, 2022, the District Court issued an opinion granting the Company’s motion in part and precluding Dr. Goldberg’s damages expert from testifying on all but two issues. The Company anticipates that a briefing schedule for motions for summary judgment will be entered by the Court. Delaware Litigation Involving Dr. Goldberg On February 20, 2019, MT initiated a suit against Dr. Goldberg in the Court of Chancery of the State of Delaware (the “Delaware Court”), alleging, among other things, breach of fiduciary duty as a director and officer of MT and conversion, and to obtain a declaratory judgment that the transactions Dr. Goldberg caused MT to effect are void. On June 12, 2019, the Delaware Court found that Dr. Goldberg’s actions were not authorized in compliance with the Delaware General Corporate Law. Specifically, the Delaware Court found that Dr. Goldberg’s creation of a new subsidiary of MT and the purported assignment by Dr. Goldberg of MT’s intellectual property to that subsidiary were void. The Delaware Court’s ruling follows the order on May 23, 2019 in the case, in which it found Dr. Goldberg in contempt of its prior order holding Dr. Goldberg responsible for the payment of MT’s fees and costs to cure the damages caused by Dr. Goldberg’s contempt. On June 23, 2021, the Delaware Court ruled in favor of MT and against Dr. Goldberg, finding that Dr. Goldberg breached his fiduciary duties to MT. Specifically, the Delaware Court ruled: “Dr. Goldberg attempted to take for himself that which belonged to [MT]. In doing so, he breached his duty of loyalty to [MT] stockholders. [MT] was absolutely justified in bringing this action to remedy (in this case undo) the harm caused by Dr. Goldberg’s misconduct.” The Delaware Court disagreed with MT’s arguments regarding damages and, other than awarding nominal damages, declined to award additional relief beyond that which it had previously granted. With respect to MT’s claim for conversion, the Delaware Court found that the claim was not supported because “Dr. Goldberg confirmed that he currently does not own or possess any intellectual property related to either Navidea or [MT]” and that “any IP Dr. Goldberg created while at Navidea or any of its subsidiaries was and remains the property of Navidea and its subsidiaries.” In addition, the Delaware Court denied Dr. Goldberg’s motion to hold MT’s directors and CEO in contempt, denied Dr. Goldberg’s motion to dismiss the lawsuit against him, and granted MT’s motion to dismiss Dr. Goldberg’s petition to remove MT’s board members. On December 9, 2021, Dr. Goldberg was ordered to reimburse MT in the amount of $ 66,796.33 NYSE American Continued Listing Standards On January 28, 2022, the Company received a notification from the NYSE American LLC (the “NYSE American”) stating that the Company was not in compliance the $6.0 million stockholders’ equity requirement of Section 1003(a)(iii) of the NYSE American Company Guide. As required by the NYSE American, the Company submitted a plan to the NYSE American by February 28, 2022 advising of actions it has taken or will take to regain compliance with the continued listing standards by July 28, 2023. On April 8, 2022, the Company received a notification (the “Acceptance Letter”) from the NYSE American that the Company’s plan to regain compliance was accepted. The Acceptance Letter also stated that the Company is also not in compliance with Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide, which require an issuer to have stockholders’ equity of (i) $2.0 million or more if it has reported losses from continuing operations and/or net losses in two out of its three most recent fiscal years, and (ii) $4.0 million or more if it has reported losses from continuing operations in three out of its four most recent fiscal years. The Acceptance Letter noted that the Company had stockholders’ equity of $624,743 as of December 31, 2021 and has reported net losses from continuing operations in its five most recent fiscal years ended December 31, 2021. The NYSE American has granted the Company a plan period through July 28, 2023 to regain compliance with Sections 1003(a)(i), (ii) and (iii). If the Company is not in compliance with all continued listing standards by that date or if the Company does not make progress consistent with the plan during the plan period, the NYSE American may commence delisting procedures.

Note 13 - Equity

Note 13 - Equity	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	13. Equity Platinum Settlement As discussed in Note 12, Platinum and the Company settled their dispute and Platinum’s lawsuit was dismissed in January 2022. As part of the settlement, Platinum returned their six shares of MT Preferred Stock, representing 60% of the noncontrolling interest in MT, to the Company. Prior to the settlement, the carrying amount of the noncontrolling interest in MT was $731,299. As a result of the settlement and the return of six shares of MT Preferred Stock, the Company recorded a reduction of the noncontrolling interest in MT and an increase in additional paid-in capital of $438,778. Series D Preferred Stock On August 31, 2020, the Company entered into a Stock Purchase Agreement and Letter of Investment Intent (the “Series D Preferred Stock Purchase Agreement”) with Keystone pursuant to which the Company agreed to issue to Keystone 150,000 shares of newly-designated Series D Redeemable Convertible Preferred Stock (the “Series D Preferred Stock”) for an aggregate purchase price of $15.0 million. Pursuant to the Series D Preferred Stock Purchase Agreement, Keystone agreed to purchase Series D Preferred Stock in amounts to be determined by Keystone in one or more closings before the end of the nine-month period following the date when the Company’s prospectus supplement to its existing registration statement on Form S-3 was filed with the SEC, provided that all of the Series D Preferred Stock must be purchased by such date. Holders of the Series D Preferred Stock had the option to convert some or all of the Series D Preferred Stock into shares of the Company’s Common Stock at a 10% discount to market (the “Series D Conversion Shares”), provided that the Company could not issue such Series D Conversion Shares in excess of 19.99% of the number of shares of Company common stock outstanding as of the date of the investment without shareholder approval, which the Company was not required to seek. The Series D Preferred Stock was convertible into a maximum of 5,147,000 shares of Common Stock. Through July 7, 2021, Keystone purchased 72,500 shares of Series D Preferred Stock pursuant to the Series D Preferred Stock Purchase Agreement for an aggregate purchase price of $7.25 million, leaving a remaining balance of 77,500 shares of Series D Preferred Stock to be purchased by Keystone. The 72,500 shares of Series D Preferred Stock were subsequently converted into 3,778,789 shares of Common Stock. Of those amounts, 54,750 and 17,750 shares of Series D Preferred Stock were purchased and converted into 2,951,509 and 827,280 shares of Common Stock during 2021 and 2020, respectively. On July 8, 2021, the Company entered into an Amendment to Stock Purchase Agreement and Letter of Investment Intent (the “Series D Amendment”) with Keystone pursuant to which Keystone purchased 22,077 shares of Series D Preferred Stock for an aggregate purchase price of approximately $2.2 million. After purchasing the 22,077 shares, Keystone has no further right or obligation to purchase shares of Series D Preferred Stock. Including the purchases pursuant to the Series D Amendment, Keystone’s purchases of Series D Preferred Stock pursuant to the Series D Purchase Agreement during the year ended December 31, 2021 totaled 76,827 shares of Series D Preferred Stock for an aggregate purchase price of approximately $7.7 million. The Series D Amendment also contained a customary mutual release provision. All of the outstanding shares of Series D Preferred Stock were exchanged and cancelled pursuant to the Rights Offering completed in August 2022. There were 0 and 22,077 shares of Series D Preferred Stock outstanding as of December 31, 2022 and 2021, respectively. Series E Preferred Stock On March 2, 2021, the Company entered into a Series E Preferred Stock Purchase Agreement with an existing accredited investor, John K. Scott, Jr. pursuant to which the Company issued to Mr. Scott 50,000 shares of Series E Preferred Stock for an aggregate purchase price of $5.0 million. Under the Series E Preferred Stock Purchase Agreement, Mr. Scott was granted a right of first offer with respect to future issuances of Company securities (the “Right of First Offer”); provided, however, that in no event shall Mr. Scott have such right if the acquisition of any of such securities would result in Mr. Scott beneficially holding more than 33.33% of the Company’s outstanding Common Stock on an as-converted basis, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder (the “Share Cap”). In the event that Mr. Scott did not exercise the Right of First Offer, the Company would have then been entitled to offer and sell the new securities to any third party at a price not less than, and upon terms no more favorable to the offeree than, those offered to Mr. Scott (a “Third Party Offering”). Pursuant to the Series E Preferred Stock Purchase Agreement, Mr. Scott also had the option to purchase up to 33.33% of the new securities offered in a Third-Party Offering at the same price and upon the terms available to the other purchaser(s) (the “Preemptive Right”); provided, however, that in no event could Mr. Scott acquire new Company securities in a Third-Party Offering to the extent the acquisition thereof would violate the Share Cap. The Right of First Offer and the Preemptive Right expired on December 31, 2021. In connection with the private placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), pursuant to which, among other things, the Company prepared and filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 to register for resale the maximum number of Series E Conversion Shares (as defined below) issuable upon conversion of the Series E Preferred Stock. In the event that both (i) the number of shares of Common Stock beneficially held by Mr. Scott fell below 20% of the outstanding Common Stock on an as-converted basis, as determined in accordance with Section 13(d) of the Exchange Act and the rules thereunder, and (ii) Mr. Scott was an affiliate (as that term is defined under Rule 144) at the time of the Reload Request (as defined below), the Company, upon written request from Mr. Scott (the “Reload Request”), would have been required prepare and file with the SEC one, and only one, additional registration statement covering the resale of those shares of Common Stock owned by Mr. Scott as of the date of the Reload Request that, as of such time, were not registered for resale under the Securities Act of 1933, as amended (the “Securities Act”). The securities issued in the offering were not registered under the Securities Act, and could not have been offered or sold absent registration or availability of an applicable exemption from registration. Except with respect to transactions which may adversely affect any right, preference, privilege or voting power of the Series E Preferred Stock, the Series E Preferred Stock had no voting rights. Whenever the Company’s Board of Directors declared a dividend on Common Stock, each record holder of a share of Series E Preferred Stock on the record date set by the Board of Directors would have been entitled to receive an amount equal to such dividend declared on one share of Common Stock multiplied by the number of shares of Common Stock (the “Series E Conversion Shares”) into which such share of Series E Preferred Stock could have been converted on the record date, without regard to any conversion limitations in the Series E Preferred Certificate of Designation of Preferences, Rights and Limitations (the “Series E Preferred Certificate”). Holders of the Series E Preferred Stock could have converted some or all of the Series E Preferred Stock into Series E Conversion Shares at a fixed price of $2.30 per Series E Conversion Share, provided that the aggregate number of Series E Conversion Shares issued pursuant to the Series E Preferred Certificate could not have exceeded the Share Cap without shareholder approval, which the Company was not required to seek. The Company had the right to redeem any outstanding shares of Series E Preferred Stock at a price of $110 per share at any time on or prior to the one-year anniversary of the issuance date, payable in cash. On January 31, 2022, pursuant to the Series E Preferred Certificate dated March 2, 2021, Mr. Scott exercised his option to extend the Conversion Deadline (as defined therein) for an additional period of six months. All of the outstanding shares of Series E Preferred Stock were exchanged and cancelled pursuant to the Stock Exchange Agreement in April 2022. There were 0 and 50,000 shares of Series E Preferred Stock outstanding as of December 31, 2022 and 2021, respectively. NOL Rights Agreement On April 7, 2022, the Company’s Board of Directors adopted an NOL rights plan in the form of a Section 382 Rights Agreement (“NOL Rights Agreement”) to preserve and protect the Company’s net operating loss carryforwards (“NOLs”) and other tax assets. As of December 31, 2022, the Company had approximately $175 million of NOLs available to offset future federal taxable income. Under the NOL Rights Agreement, the Board declared a non-taxable dividend of one preferred share purchase right for each outstanding share of common stock of the Company, each right initially representing the right to purchase one one-thousandth The rights issued under the NOL Rights Agreement will expire on the earliest of (i) April 6, 2025; (ii) the effective date of the repeal of Section 382 or any successor statute if the Board determines in its sole discretion that the NOL Rights Agreement is no longer necessary or desirable for the preservation of NOLs or other tax benefits; (iii) the first day of a taxable year of the Company to which the Board determines in its sole discretion that no NOLs or other Tax Benefits may be carried forward; or (iv) the day following the certification of the voting results of the Company’s 2022 annual meeting of stockholders if at or before such annual meeting a proposal to approve the NOL Rights Agreement has not been approved by stockholders, unless the Rights are earlier redeemed or exchanged by the Company, or upon the occurrence of certain transactions. See Note 19(a). Stock Exchange and Loan Agreement On April 10, 2022, the Company entered into a Stock Exchange Agreement with John K. Scott, Jr., pursuant to which Mr. Scott agreed to make a loan to the Company in the principal amount of up to $2.5 million, of which $1.5 million was funded on the closing date. Mr. Scott funded an additional $1.0 million on July 1, 2022. The outstanding balance of the loan, which is evidenced by a Bridge Note, bears interest at a rate of 8% per annum, with payments of interest only to be made monthly over a period of two years. All outstanding principal and accrued and unpaid interest under the Bridge Note is due and payable on the second anniversary of the Stock Exchange Agreement. The Company’s obligations under the Bridge Note are secured by a first priority security interest in all of the Company’s assets and personal property pursuant to a Security Agreement. As consideration and a partial inducement for Mr. Scott to make the loan, at the closing, Mr. Scott delivered 50,000 shares of Series E Preferred Stock, representing 100% of the outstanding Series E Preferred Stock, to the Company in exchange for the Company’s issuance of 1,740 shares of Series F Convertible Preferred Stock and 3,260 shares of Series G Preferred Stock. The number of shares of Common Stock that the Company may issue to Mr. Scott upon conversion of the Series F Preferred stock may not exceed that number of shares that would result in Mr. Scott owning more than 33.33% of the Company’s then outstanding shares of Common Stock unless the Company obtains stockholder approval to issue more than the 33.33% cap. The closing of the loan and stock exchange took place on April 12, 2022. In connection with the Stock Exchange Agreement, the Company entered into a Registration Rights Agreement with Mr. Scott, pursuant to which the Company agreed to file a registration statement with the SEC to register the resale of the shares issuable to Mr. Scott upon conversion of the Series F Preferred Stock. Rights Offering On August 30, 2022, the Company closed on the Rights Offering to its stockholders and certain warrant holders as of August 3, 2022 of the right to purchase up to 35,000 Units at a subscription price of $1,000 per Unit. The Rights Offering resulted in the sale of 10,423 Units for aggregate gross proceeds of $6,173,000 to the Company. Each Unit consisted of one share of Series I Preferred Stock which is convertible into 2,222 shares of Common Stock and one Warrant to purchase an additional 2,222 shares of Common Stock at $0.45 per share. If exercised, additional gross proceeds of up to $11.6 million may be received through the exercise of Warrants issued in the Rights Offering. Both the Series I Preferred Stock and the Warrants are standalone instruments and each is classified as stockholders’ equity. We measured the fair value of the Series I Preferred Stock based on the market price of the underlying Common Stock on the closing date of the Rights Offering. We measured the fair value of the Warrants using the Black-Scholes option pricing model as of the closing date of the Rights Offering. The assumptions used to calculate fair value of the Warrants included volatility of 89.25%, a risk-free rate of 3.27% and expected dividends of $0. We then allocated the total value of the Units sold in the Rights Offering based on the relative fair value of the Series I Preferred Stock and the Warrants. Of the $10,423,000 total value of Units sold in the Rights Offering, we allocated $6,278,815 to the Series I Preferred Stock and $4,144,185 to the Warrants. Certain participants in the Rights Offering had the ability to pay the subscription price for their Units by cancelling or exchanging their shares of Series D Preferred Stock, Series F Preferred Stock and/or Series G Preferred Stock and the Company’s indebtedness evidenced by the Bridge Note, instead of paying by check or wire transfer of funds. The fair market value of the shares of each series of preferred stock and the Bridge Note to be cancelled or exchanged in the Rights Offering was determined by the Company’s Board of Directors with the assistance of an independent appraisal obtained by the Company. In order to help maximize Navidea’s ability to use its NOLs and other tax benefits in future years, Navidea’s Board of Directors exercised its discretion to limit the number of Units that John K. Scott, Jr. could purchase to 2,400 Units, which Mr. Scott elected to pay for by exchanging and surrendering all of his shares of Series F Preferred Stock. Of the total 10,423 Units sold in the Rights Offering, 4,250 Units were sold pursuant to the exchange and surrender of all outstanding shares of Navidea’s Series D Preferred Stock and Series F Preferred Stock. Neither the Series G Preferred Stock nor the Bridge Note was exchanged or cancelled pursuant to the Rights Offering. In accordance with U.S. GAAP, we determined that the fair value of the Series D Preferred Stock and Series F Preferred Stock that was surrendered pursuant to the Rights Offering was approximately $2,212,114. The total fair value of the Units that were issued in exchange for the Series D Preferred Stock and Series F Preferred Stock was $4,250,000. Therefore, the incremental fair value received by the holders of the Series D Preferred Stock and Series F Preferred Stock was approximately $2,037,886. The incremental amount was recognized as a deemed dividend in the Company’s consolidated statement of operations for the year ended December 31, 2022. Net proceeds after deducting fees and expenses of $998,401 related to the Rights Offering will be used to fund our pivotal Phase 3 clinical trial for RA, obtaining regulatory approvals, working capital, and for general corporate purposes. 401(k) Employer Match During the years ended December 31, 2022 and 2021, we issued 53,238 and 30,018 shares of our Common Stock as matching contributions to our 401(k) Plan which were valued at $44,720 and $76,846, respectively. Bonuses Paid in Stock During the year ended December 31, 2022, we issued 44,782 shares of our Common Stock to certain of our employees as partial payment in lieu of cash for their 2021 bonuses, which were valued at $24,847. Long Term Incentive Plan On September 9, 2022, the Company’s Board of Directors approved and adopted the terms and conditions of a long-term incentive plan (“LTIP”) that seeks to motivate and reward employees. The LTIP provides for the issuance of share-based awards to employees of the Company pursuant to the 2014 Plan. The target amount of the stock award under the LTIP for each employee was determined based on a variety of factors. Payout of the stock awards is based on the achievement of pre-established performance objectives and goals related to financing and U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) regulatory milestones for the Company’s Phase 3 clinical trial for rheumatoid arthritis (NAV3-33). The financing and EMA regulatory milestones will each comprise 5% of the total stock award payout for participants; the FDA regulatory milestones will comprise the remaining 90%. The payout amount is subject to downward adjustment based on the timing of the achievement of the particular milestone. In order to receive the payout, the participant generally will be required to continue to be employed through the date of the payout. Upon issuance of the stock award, the participant will be 100% vested in the stock award. Although the Company did not fully satisfy the financing milestone, based on completion of the Rights Offering, the Board of Directors decided to pay out 5% of the target stock award to all participants under the LTIP. During the year ended December 31, 2022, we issued 70,500 shares of Common Stock to all participants under the LTIP, which were valued at $19,740. Stock Warrants On October 25, 2022, the Holders of Series LL warrants to purchase 218,264 shares of Common Stock at $0.20 per share exercised those warrants on a cashless basis, resulting in the issuance of 62,361 shares of Common Stock. As of December 31, 2022, there are warrants outstanding to purchase 23,363,966 shares of Common Stock. The warrants are exercisable at prices ranging from $0.50 to $49.80 per share with a weighted average exercise price per share of $0.54. The warrants have remaining outstanding terms ranging from 0.5 to 4.7 years. The following table summarizes information about our outstanding warrants as of December 31, 2022: Exercise Price Number of Warrants Expiration Date Series HH $ 49.80 15,060 6/25/2023 Series OO 0.9375 189,000 6/13/2024 Series PP 0.50 23,159,906 8/30/2027 Total warrants $ 0.54 * 23,363,966 * Weighted average exercise price. Common Stock Reserved As of December 31, 2022, we have reserved 24,066,771 shares of authorized Common Stock for the exercise of all outstanding stock options and warrants, 21,064,560 shares for the issuance of Common Stock upon conversion of Series I Preferred Stock and 102,869 shares to be issued to certain directors who elected to defer receipt of stock for director fees until the Company raises sufficient additional capital. An additional 250,000 shares of Common Stock have been reserved for issuance to Dr. Goldberg related to the Goldberg Agreement. See Note 12.

Note 14- Income Taxes

Note 14- Income Taxes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income Taxes The components of our deferred tax assets (“DTAs”) as of December 31, 2022 and 2021 are summarized in the following table: As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 39,200,586 $ 36,793,074 R&D credit carryforwards* 9,256,968 9,501,299 Stock compensation 286,724 481,098 Intangibles 455,959 567,213 Accrued expenses 710,940 — Capitalized §174 expenses 1,116,433 — Disallowed interest expense — 851,247 Temporary differences 196,575 305,974 Deferred tax assets before valuation allowance 51,224,185 48,499,905 Valuation allowance (51,224,185 ) (48,499,905 ) Net deferred tax assets $ — $ — * Includes U.S. R&D credit carryforwards of $8,868,343 and state R&D credit carryforwards of $388,625 as of December 31, 2022. footnote Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not that some or all of the DTAs may not be realized. Due to the uncertainty surrounding the realization of these DTAs in future tax returns, all of the DTAs have been fully offset by a valuation allowance as of December 31, 2022 and 2021. In assessing the realizability of DTAs, management considers whether it is more likely than not that some portion or all of the DTAs will not be realized. The ultimate realization of DTAs is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods) and projected future taxable income in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the DTAs are deductible, management believes it is more likely than not that the Company will not realize the benefits of these deductible differences or tax carryforwards as of December 31, 2022. As of December 31, 2022 and 2021, we had U.S. net operating loss carryforwards of $175,127,244 and $168,776,440, respectively. As of December 31, 2022 and 2021, we also had state net operating loss carryforwards of $20,068,842. The state net operating loss carryforwards will begin expiring in 2027. There were no expirations of U.S. NOL carryforwards during 2022 or 2021. U.S. R&D credit carryforwards of $5,350 and $0 expired during 2022 and 2021, respectively. The details of our U.S. net operating loss and federal R&D credit carryforward amounts and expiration dates as of December 31, 2022 are summarized in the following table: As of December 31, 2022 U.S. Net Operating Loss Carryforwards U.S. R&D Credit Carryforwards Generated Expiration Amount Generated Expiration Amount 2003 2023 $ — 2003 2023 $ 2,905 2004 2024 — 2004 2024 22,861 2005 2025 — 2005 2025 218,332 2006 2026 — 2006 2026 365,541 2007 2027 — 2007 2027 342,898 2008 2028 — 2008 2028 531,539 2009 2029 — 2009 2029 596,843 2010 2030 — 2010 2030 1,094,449 2011 2031 — 2011 2031 1,950,744 2012 2032 18,898,490 2012 2032 468,008 2013 2033 37,450,522 2013 2033 681,772 2014 2034 34,088,874 2014 2034 816,116 2015 2035 25,073,846 2015 2035 492,732 2016 2036 15,581,209 2016 2036 262,257 2017 2037 — 2017 2037 387,892 2018 N/A — 2018 2038 197,547 2019 N/A 11,245,808 2019 2039 213,065 2020 N/A 11,018,478 2020 2040 222,842 2021 N/A 15,419,213 2021 2041 — 2022 N/A 6,350,804 2022 2042 — Total carryforwards $ 175,127,244 Total carryforwards $ 8,868,343 Under Sections 382 and 383 of the Internal Revenue Code (“IRC”) of 1986, as amended, the utilization of U.S. net operating loss and R&D tax credit carryforwards may be limited under the change in stock ownership rules of the IRC. The Company completed a Section 382 analysis through December 31, 2022 and believes that a Section 382 ownership change has not occurred. Reconciliations between the statutory federal income tax rate and our effective tax rate for continuing operations are presented in the following table: 2022 2021 Amount % Amount % Benefit at statutory rate $ (3,137,533 ) (21.0 )% $ (2,460,126 ) (21.0 )% Adjustments to valuation allowance 2,724,281 17.9 % 2,676,868 22.9 % Adjustments to R&D credit carryforwards — — (199,589 ) (1.7 )% Permanent items and other 413,252 3.1 % (1,110 ) (0.1 )% Provision (benefit) per financial statements $ — $ 16,043

Note 15 - Segments

Note 15 - Segments	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two The information in the following tables is derived directly from each reportable segment’s financial reporting: Year Ended December 31, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 14,645 — — 14,645 Grant and other revenue 51,007 — — 51,007 Total revenue 65,652 — — 65,652 Cost of revenue 1,941 — — 1,941 Adjustments for expired and expiring inventory 183,006 — — 183,006 Research and development expenses 5,501,134 468,640 — 5,969,774 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 4,530 7,861,477 7,866,007 Depreciation and amortization (2) 29,387 — 66,432 95,819 Loss from operations (3) (5,649,816 ) (473,170 ) (7,927,909 ) (14,050,895 ) Other expense, net (4) — — (1,126,261 ) (1,126,261 ) Net loss (5,649,816 ) (473,170 ) (9,054,170 ) (15,177,156 ) Total assets, net of depreciation and amortization: United States $ 610 $ — $ 3,817,195 $ 3,817,805 International 539,188 — 14,613 553,801 Capital expenditures 54,650 — 8,436 63,086 Year Ended December 31, 2021 Diagnostics Therapeutics Corporate Total Royalty revenue $ — $ — $ — $ — License revenue 45,615 — — 45,615 Grant and other revenue 485,898 — — 485,898 Total revenue 531,513 — — 531,513 Research and development expenses, excluding depreciation and amortization 4,488,177 653,733 — 5,141,910 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 4,438 7,368,623 7,373,061 Depreciation and amortization (2) 24,162 — 52,792 76,954 Loss from operations (3) (3,980,826 ) (658,171 ) (7,421,415 ) (12,060,412 ) Other income (4) — — 345,524 345,524 Provision for income taxes (5,452 ) (901 ) (9,690 ) (16,043 ) Net loss (3,986,278 ) (659,072 ) (7,085,581 ) (11,730,931 ) Total assets, net of depreciation and amortization: United States $ 107,931 $ — $ 6,326,031 $ 6,433,962 International 210,281 — 590 210,871 Capital expenditures — — 25,218 25,218 (1) General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT. (2) Depreciation and amortization are reflected in selling, general and administrative expenses ($95,819 and $76,954 for the years ended December 31, 2022 and 2021, respectively). (3) Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT. (4) Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 16 - Material Agreements

Note 16 - Material Agreements	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Agreements Disclosure [Text Block]	16. Material Agreements a. Research and Development Agreements: In connection with the sale of the rights to sell Tc99m tilmanocept in the United States, Canada and Mexico to Cardinal Health 414, LLC (“Cardinal Health 414”), the Company amended and restated its Tc99m tilmanocept license agreement with UCSD pursuant to which UCSD granted a license to the Company to exploit certain intellectual property rights owned by UCSD and, separately, Cardinal Health 414 entered into a license agreement with UCSD pursuant to which UCSD granted a license to Cardinal Health 414 to exploit certain intellectual property rights owned by UCSD for Cardinal Health 414 to sell Tc99m tilmanocept in the United States, Canada and Mexico. Total costs related to the UCSD license agreement for net sales and royalties of Tc99m tilmanocept outside the United States, Canada and Mexico were $868 and $4,339 in 2022 and 2021, respectively, and were recorded in cost of revenue and as a reduction in license revenue, respectively. Total costs related to the UCSD license agreement for annual maintenance fees, milestones and patent-related costs were $(101,409) and $20,702 in 2022 and 2021, respectively, and were recorded in R&D expenses. Changes in regulatory strategy resulted in the reversal of certain previously recorded expenses related to the Tc99m Tilmanocept license agreement during the year ended December 31, 2022. In July 2014, the Company executed an expanded license agreement for the exclusive world-wide rights to all diagnostic and therapeutic uses of tilmanocept (other than Tc99m tilmanocept used in lymphatic mapping). The license agreement is effective until the third anniversary of the expiration date of the longest-lived underlying patent. Under the terms of the license agreement, UCSD has granted us the exclusive rights to make, use, sell, offer for sale and import licensed products as defined in the agreement and to practice the defined licensed methods during the term of the agreement. We may also sublicense the patent rights, subject to certain sublicense terms as defined in the agreement. As consideration for the license rights, we agreed to pay UCSD a license issue fee of $25,000 and license maintenance fees of $25,000 per year. We also agreed to make payments to UCSD upon successfully reaching certain clinical, regulatory and cumulative sales milestones, and a royalty on net sales of licensed products subject to a $25,000 minimum annual royalty. In addition, we agreed to reimburse UCSD for all patent-related costs and to meet certain diligence requirements. Total costs related to the UCSD license agreement for tilmanocept were $25,000 in both 2022 and 2021, and were recorded in R&D expenses. See Note 19(a). b. Separation Agreement:

Note 17 - Employee Benefit Plan

Note 17 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	17. Employee Benefit Plan We maintain an employee benefit plan under Section 401(k) of the IRC (the “401(k) Plan”). The 401(k) Plan allows employees to make contributions and we may, but are not obligated to, match a portion of the employee’s contribution with our Common Stock, up to a defined maximum. The Company’s current matching contribution rate is 100% of employee contributions to the 401(k) Plan up to 6% of the employee’s salary. We also pay certain expenses related to maintaining the 401(k) Plan. We recorded expenses related to the 401(k) Plan of $30,755 and $148,406 during 2022 and 2021, respectively.

Note 18 - Supplemental Disclosu

Note 18 - Supplemental Disclosure for Statements of Cash Flows	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	18. Supplemental Disclosure for Statements of Cash Flows We paid interest aggregating $136,432 and $9,015 in 2022 and 2021, respectively. During 2022 and 2021, we issued 53,238 and 30,018 shares of Common Stock, respectively, as matching contributions to our 401(k) Plan which were valued at $44,720 and $76,846, respectively. During 2022, we issued 44,782 shares of our Common Stock to certain of our employees as partial payment in lieu of cash for their 2021 bonuses, which were valued at $24,847. Also during 2022, we issued 70,500 shares of Common Stock to all participants under the LTIP, which were valued at $19,740. In November 2022, we prepaid $608,275 of insurance premiums through the issuance of a note payable to AFCO with an interest rate of 7.85%. In November 2021, we prepaid $565,760 of insurance premiums through the issuance of a note payable to IPFS with an interest rate of 4.36%. During 2022, 218,264 Series LL warrants to purchase the Company’s Common Stock were exercised on a cashless basis in exchange for issuance of 62,361 shares of Navidea Common Stock. Also during 2022, the Company recorded additional paid-in capital of $821,250 related to the difference in the value of Mr. Scott’s Series E Preferred Stock and the Series F and Series G Preferred Stock. During 2022, the Company recorded a deemed dividend of $2,037,886 related to the exchange of Series D Preferred Stock and Series F Preferred Stock for Series I Preferred Stock in the Rights Offering, and 943 shares of Series I Preferred Stock were converted into 2,095,490 shares of Common Stock.

Note 19 - Subsequent Events

Note 19 - Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	19. Subsequent Events The Company has evaluated events and transactions subsequent to December 31, 2022 and through the date these consolidated financial statements were included in this Annual Report on Form 10-K and filed with the SEC. a. Amendment to NOL Rights Agreement: b. UCSD Amendment:

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Nature of Operations [Policy Text Block]	a. Organization and Nature of Operations:
Consolidation, Policy [Policy Text Block]	b. Principles of Consolidation:
Use of Estimates, Policy [Policy Text Block]	c. Use of Estimates:
Revenue [Policy Text Block]	d. Revenue Recognition:
Share-Based Payment Arrangement [Policy Text Block]	e. Stock-Based Compensation: one four ten 2022 2021 Expected volatility 92% - 100% 90% - 102% Weighted-average volatility 94% 95% Expected forfeiture rate 8.4% - 8.9% 5.2% - 9.0% Expected term (in years) 6.2 - 6.3 5.5 - 6.2 Risk-free rate 1.7% - 2.5% 0.6% - 1.4% Expected dividends — —
Earnings Per Share, Policy [Policy Text Block]	f. Net Loss Per Share:
Research and Development Expense, Policy [Policy Text Block]	g. Research and Development Costs:
Receivable [Policy Text Block]	h. Receivables:
Inventory, Policy [Policy Text Block]	i. Inventory:
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	j. Intangible Assets:
Lessee, Leases [Policy Text Block]	k. Leases:
Commitments and Contingencies, Policy [Policy Text Block]	l. Contingent Liabilities: Contingencies not
Debt, Policy [Policy Text Block]	m. Debt: Debt
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	n. Preferred Stock: Distinguishing Liabilities from Equity Derivatives and Hedging Debt Presentation in Financial Statements of Redeemable Preferred Stocks Accounting for Convertible Instruments and Contracts in an Entity s Own Equity o. Preferred Stock Issued with Warrants: Distinguishing Liabilities from Equity Derivatives and Hedging Presentation in Financial Statements of Redeemable Preferred Stocks i. Series I Preferred Stock: ii. Warrants:
Income Tax, Policy [Policy Text Block]	p. Income Taxes: no
New Accounting Pronouncements, Policy [Policy Text Block]	q. Recently Adopted Accounting Standards: Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Disclosures by Business Entities about Government Assistance r. Accounting Standards to be Adopted: Measurement of Credit Losses on Financial Instruments

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2022 2021 Expected volatility 92% - 100% 90% - 102% Weighted-average volatility 94% 95% Expected forfeiture rate 8.4% - 8.9% 5.2% - 9.0% Expected term (in years) 6.2 - 6.3 5.5 - 6.2 Risk-free rate 1.7% - 2.5% 0.6% - 1.4% Expected dividends — —

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Years Ended December 31, 2022 2021 Sales revenue: Tc99m tilmanocept – Europe $ 14,035 $ — Tc99m tilmanocept – Australia 610 — Total sales revenue 14,645 — License revenue: Tc99m tilmanocept - Europe $ — $ 45,615
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Years Ended December 31, 2022 2021 Total deferred revenue related to contracts with customers, beginning of period $ 700,000 $ 700,000 Deferred revenue related to milestones achieved 100,000 — Deferred revenue related to milestones achieved, written off due to contract renegotiations (100,000 ) — Total deferred revenue related to contracts with customers, end of period $ 700,000 $ 700,000

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Year Ended December 31, 2022 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2022 919,790 $ 5.67 Granted 12,500 0.83 Canceled and forfeited (154,955 ) 2.37 Expired (74,530 ) 23.48 Outstanding, December 31, 2022 702,805 $ 4.42 5.5 $ — Exercisable, December 31, 2022 537,390 $ 5.31 4.5 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Year Ended December 31, 2022 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2022 95,000 $ 1.40 Granted 30,000 0.24 Vested (35,000 ) 1.45 Unvested, December 31, 2022 90,000 $ 0.99

Note 6 - Receivables (Tables)

Note 6 - Receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	2022 2021 Sales revenue $ 610 $ — Related parties — 86,796 License revenue — 1,021 Grant revenue — 919 Other 20 4,256 Total stock subscriptions and other receivables $ 630 $ 92,992

Note 7 - Inventory, Net (Tables

Note 7 - Inventory, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2022 December 31, 2021 Materials $ 27,405 $ 50,000 Work in process 399,939 — Finished goods 131,804 101,155 Reserve for expiring finished goods (131,804 ) — Total inventory, net $ 427,344 $ 151,155

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	Useful Life (in years) 2022 2021 Purchased software 3 $ 320,435 $ 320,435 Production machinery and equipment 5 175,460 214,356 Other machinery and equipment, primarily computers and research equipment 3 – 5 311,973 304,492 Leasehold improvements* Term of Lease 23,511 23,511 Furniture and fixtures 7 4,466 3,512 Total property and equipment $ 835,845 $ 866,306

Note 9 - Accounts Payable, Ac_2

Note 9 - Accounts Payable, Accrued Liabilities and Other (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2022 2021 Contracted services $ 5,667,105 $ 1,913,756 Compensation 788,036 1,194,719 Other 1,621 — Total accrued liabilities and other $ 6,456,762 $ 3,108,515

Note 11 - Leases (Tables)

Note 11 - Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2023 $ 19,699 2024 1,355 Total undiscounted operating lease payments 21,054 Less imputed interest 766 Present value of operating lease liabilities $ 20,288
Lessee, Operating Lease, Assets and Liabilities [Table Text Block]	Balance Sheet Classification Current lease liabilities $ 18,976 Noncurrent lease liabilities 1,312 Total operating lease liabilities $ 20,288
Lessee, Leases, Other Information [Table Text Block]	Other Information Weighted-average remaining lease term for operating leases (in years) 0.7 Weighted-average discount rate for operating leases 10.53 %

Note 13 - Equity (Tables)

Note 13 - Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Price Number of Warrants Expiration Date Series HH $ 49.80 15,060 6/25/2023 Series OO 0.9375 189,000 6/13/2024 Series PP 0.50 23,159,906 8/30/2027 Total warrants $ 0.54 * 23,363,966

Note 14- Income Taxes (Tables)

Note 14- Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 39,200,586 $ 36,793,074 R&D credit carryforwards* 9,256,968 9,501,299 Stock compensation 286,724 481,098 Intangibles 455,959 567,213 Accrued expenses 710,940 — Capitalized §174 expenses 1,116,433 — Disallowed interest expense — 851,247 Temporary differences 196,575 305,974 Deferred tax assets before valuation allowance 51,224,185 48,499,905 Valuation allowance (51,224,185 ) (48,499,905 ) Net deferred tax assets $ — $ —
Summary of Tax Credit Carryforwards [Table Text Block]	As of December 31, 2022 U.S. Net Operating Loss Carryforwards U.S. R&D Credit Carryforwards Generated Expiration Amount Generated Expiration Amount 2003 2023 $ — 2003 2023 $ 2,905 2004 2024 — 2004 2024 22,861 2005 2025 — 2005 2025 218,332 2006 2026 — 2006 2026 365,541 2007 2027 — 2007 2027 342,898 2008 2028 — 2008 2028 531,539 2009 2029 — 2009 2029 596,843 2010 2030 — 2010 2030 1,094,449 2011 2031 — 2011 2031 1,950,744 2012 2032 18,898,490 2012 2032 468,008 2013 2033 37,450,522 2013 2033 681,772 2014 2034 34,088,874 2014 2034 816,116 2015 2035 25,073,846 2015 2035 492,732 2016 2036 15,581,209 2016 2036 262,257 2017 2037 — 2017 2037 387,892 2018 N/A — 2018 2038 197,547 2019 N/A 11,245,808 2019 2039 213,065 2020 N/A 11,018,478 2020 2040 222,842 2021 N/A 15,419,213 2021 2041 — 2022 N/A 6,350,804 2022 2042 — Total carryforwards $ 175,127,244 Total carryforwards $ 8,868,343
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2022 2021 Amount % Amount % Benefit at statutory rate $ (3,137,533 ) (21.0 )% $ (2,460,126 ) (21.0 )% Adjustments to valuation allowance 2,724,281 17.9 % 2,676,868 22.9 % Adjustments to R&D credit carryforwards — — (199,589 ) (1.7 )% Permanent items and other 413,252 3.1 % (1,110 ) (0.1 )% Provision (benefit) per financial statements $ — $ 16,043

Note 15 - Segments (Tables)

Note 15 - Segments (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended December 31, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 14,645 — — 14,645 Grant and other revenue 51,007 — — 51,007 Total revenue 65,652 — — 65,652 Cost of revenue 1,941 — — 1,941 Adjustments for expired and expiring inventory 183,006 — — 183,006 Research and development expenses 5,501,134 468,640 — 5,969,774 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 4,530 7,861,477 7,866,007 Depreciation and amortization (2) 29,387 — 66,432 95,819 Loss from operations (3) (5,649,816 ) (473,170 ) (7,927,909 ) (14,050,895 ) Other expense, net (4) — — (1,126,261 ) (1,126,261 ) Net loss (5,649,816 ) (473,170 ) (9,054,170 ) (15,177,156 ) Total assets, net of depreciation and amortization: United States $ 610 $ — $ 3,817,195 $ 3,817,805 International 539,188 — 14,613 553,801 Capital expenditures 54,650 — 8,436 63,086 Year Ended December 31, 2021 Diagnostics Therapeutics Corporate Total Royalty revenue $ — $ — $ — $ — License revenue 45,615 — — 45,615 Grant and other revenue 485,898 — — 485,898 Total revenue 531,513 — — 531,513 Research and development expenses, excluding depreciation and amortization 4,488,177 653,733 — 5,141,910 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 4,438 7,368,623 7,373,061 Depreciation and amortization (2) 24,162 — 52,792 76,954 Loss from operations (3) (3,980,826 ) (658,171 ) (7,421,415 ) (12,060,412 ) Other income (4) — — 345,524 345,524 Provision for income taxes (5,452 ) (901 ) (9,690 ) (16,043 ) Net loss (3,986,278 ) (659,072 ) (7,085,581 ) (11,730,931 ) Total assets, net of depreciation and amortization: United States $ 107,931 $ — $ 6,326,031 $ 6,433,962 International 210,281 — 590 210,871 Capital expenditures — — 25,218 25,218

Note 1 - Organization and Sum_3

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($)		12 Months Ended
	Aug. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Patent and Trademark Costs		$ 327,263	$ 304,206
Previously Capitalized Patent Costs Abandoned		52,702	98,645
Amortization of Intangible Assets		47,590	40,151
Finite-Lived Intangible Asset, Expected Amortization, Year One		48,000
Finite-Lived Intangible Asset, Expected Amortization, Year Two		48,000
Finite-Lived Intangible Asset, Expected Amortization, Year Three		48,000
Finite-Lived Intangible Asset, Expected Amortization, Year Four		48,000
Finite-Lived Intangible Asset, Expected Amortization, Year Five		48,000
Unrecognized Tax Benefits, Ending Balance		0	0
CRG Loan Agreement, Texas Case [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 2,600,000
Loss Contingency Accrual, Ending Balance		3,385,429
Complaint By Dr. Goldberg Against Navidea and MT [Member]
Estimated Litigation Liability		0
Selling, General and Administrative Expenses [Member]
Amortization of Intangible Assets		$ 47,590	$ 40,151
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life		5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life		15 years
The 2014 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized		7,750,000
The 2014 Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period		1 year
The 2014 Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period		4 years
The 2002 and 2014 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
The 2002 and 2014 Plan [Member] | Grantee Status, Former Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		90 days
Navidea Biopharmaceuticals Limited [Member]
Noncontrolling Interest, Ownership Percentage by Parent		100%
Macrophage Therapeutics [Member]
Noncontrolling Interest, Ownership Percentage by Parent		99.96%
Navidea Europe [Member]
Noncontrolling Interest, Ownership Percentage by Parent		100%

Note 1 - Organization and Sum_4

Note 1 - Organization and Summary of Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Stock Option Awards Granted (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Weighted-average volatility	94%	95%
Expected dividends	0%	0%
Minimum [Member]
Expected volatility	92%	90%
Expected forfeiture rate	8.40%	5.20%
Expected term (in years) (Year)	6 years 2 months 12 days	5 years 6 months
Risk-free rate	1.70%	0.60%
Maximum [Member]
Expected volatility	100%	102%
Expected forfeiture rate	8.90%	9%
Expected term (in years) (Year)	6 years 3 months 18 days	6 years 2 months 12 days
Risk-free rate	2.50%	1.40%

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)		Aug. 30, 2022	Aug. 11, 2022	Aug. 03, 2022	Jul. 01, 2022	Apr. 10, 2022	Dec. 31, 2022	Oct. 11, 2022
Rights Offering, Shares Authorized		35,000		35,000
Shares Issued, Price Per Share		$ 1,000		$ 1,000
Units Issued During Period, Units, New Issues		10,423
Proceeds from Issuance or Sale of Equity, Total		$ 6,173,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	[1]						$ 0.54
Payments to Fund Clinical Research Trial		$ 998,401
API Development Funding and Access Agreement [Member]
Development Agreement, Reimbursement Amount							$ 1,850,000
Development Agreement, Reimbursement Proceeds			$ 800,000
Unit Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,222
Class of Warrant or Right, Purchase Price of Stock		$ 0.45
Class of Warrants or Rights, Warrant Proceeds if Exercised		$ 11,600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.50
Series I Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion		2,222
Units Sold in Exchange for Series D Preferred Stock [Member]
Units Issued During Period, Units, New Issues		4,250
Purchase Agreement [Member] | Vice Chairman of Board of Directors [Member]
Debt Instrument, Face Amount						$ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total					$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage						8%
CRG Loan Agreement, Texas Case [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 2,600,000
Loss Contingencies, Interest Rate								18%
Loss Contingency Accrual, Ending Balance							$ 3,385,429
[1]Weighted average exercise price.

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Contract with Customer, Payment Term, Minimum	15 days
Contract with Customer, Payment Term, Maximum (Day)	90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	$ 0
Revenue from Contract with Customer, Including Assessed Tax	14,645	$ 45,615
Contract with Customer, Asset, Impairment Loss	0	0
Capitalized Contract Cost, Net, Total	0
Sales Revenue [Member]
Contract with Customer, Asset, after Allowance for Credit Loss, Total	610	0
License [Member]
Revenue from Contract with Customer, Including Assessed Tax	0	45,615
Contract with Customer, Asset, after Allowance for Credit Loss, Total	0	1,021
Grant [Member]
Revenue Not from Contract with Customer	$ 51,007	$ 87,898
INDIA
Contract with Customer, Term of Contract (Year)	8 years
CHINA
Contract with Customer, Term of Contract (Year)	10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue from contract with customer	$ 14,645	$ 45,615
Sales Revenue [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	14,645	0
License [Member]
Revenue from contract with customer	0	45,615
License [Member] | Diagnostics Segment [Member]
Revenue from contract with customer		45,615
Europe [Member] | Sales Revenue [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	14,035	0
Europe [Member] | License [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	0	45,615
AUSTRALIA | Sales Revenue [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	$ 610	$ 0

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total deferred revenue related to contracts with customers, beginning of period	$ 700,000	$ 700,000
Deferred revenue related to milestones achieved	100,000	0
Deferred revenue related to milestones achieved, written off due to contract renegotiations	(100,000)	0
Total deferred revenue related to contracts with customers, end of period	$ 700,000	$ 700,000

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) - USD ($)		12 Months Ended
	Nov. 23, 2021	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Expense		$ 301,351	$ 471,262
Share-Based Payment Arrangement, Expense, Tax Benefit		$ 0	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number		537,390
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.65	$ 1.46
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period		0	4,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 2,500
Proceeds from Stock Options Exercised			4,240
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value		$ 0	$ 122,402
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 84,062
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 6 months
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period			4,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period		35,000	70,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 13,440	$ 112,680
Former Chief Executive Officer [Member]
Share-Based Payment Arrangement, Expense	$ 243,150
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	69,918
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	333,332
Reversal of Allocated Share Based Compensation Expense	$ 503,049
Former Chief Executive Officer [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	5 years
Former Chief Executive Officer [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period	33,333
Director [Member] | Restricted Stock [Member] | Vesting As Scheduled [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period		35,000	20,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 13,440	$ 42,730

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Outstanding at beginning of period (in shares) | shares	919,790
Outstanding at beginning of period, weighted average exercise price (in dollars per share) | $ / shares	$ 5.67
Granted (in shares) | shares	12,500
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.83
Canceled and forfeited (in shares) | shares	(154,955)
Canceled and forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 2.37
Expired (in shares) | shares	(74,530)
Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 23.48
Outstanding at end of period (in shares) | shares	702,805
Outstanding at end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 4.42
Outstanding, weighted average remaining contractual life (Year)	5 years 6 months
Outstanding, aggregate intrinsic value | $	$ 0
Exercisable at end of period (in shares) | shares	537,390
Exercisable at end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 5.31
Exercisable, weighted average remaining contractual life (Year)	4 years 6 months
Exercisable, aggregate intrinsic value | $	$ 0

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Unvested at beginning of period (in shares)	95,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share)	$ 1.40
Granted (in shares)	30,000
Granted, weighted average grant-date fair value (in dollars per share)	$ 0.24
Vested (in shares)	(35,000)	(70,000)
Vested, weighted average grant-date fair value (in dollars per share)	$ 1.45
Unvested at end of period (in shares)	90,000	95,000
Unvested at end of period, weighted average grant-date fair value (in dollars per share)	$ 0.99	$ 1.40

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	24,066,771	1,892,114
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	90,000	95,000

Note 6 - Receivables (Details T

Note 6 - Receivables (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable, Allowance for Credit Loss, Current	$ 0	$ 0

Note 6 - Receivables - Accounts

Note 6 - Receivables - Accounts and Other Receivables (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Accounts and other receivables	$ 630	$ 92,992
Sales Revenue Receivable [Member[
Accounts and other receivables	610	0
Related Party Receivables [Member]
Accounts and other receivables	0	86,796
License Revenue Receivable [Member]
Accounts and other receivables	0	1,021
Grant Revenue Receivable [Member]
Accounts and other receivables	0	919
Other Accounts Receivable [Member]
Accounts and other receivables	$ 20	$ 4,256

Note 7 - Inventory, Net (Detail

Note 7 - Inventory, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Adjustments for expired and expiring inventory	$ 183,006	$ 0
Finished Goods Inventory Expected to Expire [Member]
Adjustments for expired and expiring inventory	133,006
Expired Materials Inventory [Member]
Adjustments for expired and expiring inventory	50,000
Raw Materials [Member]
Inventory, Allocated to Manufacturing Process Development Expense	79,582	27,750
Finished Goods [Member]
Inventory, Allocated to Research and Development Expense	$ 103,955	$ 0

Note 7 - Inventory, Net - Net I

Note 7 - Inventory, Net - Net Inventory (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Materials	$ 27,405	$ 50,000
Work in process	399,939	0
Finished goods	131,804	101,155
Reserve for expiring finished goods	(131,804)	0
Total inventory, net	$ 427,344	$ 151,155

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Depreciation, Depletion and Amortization, Total	$ 48,229	$ 36,803

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Summary of Major Classes of Property and Equipment (Details) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Property and Equipment, Gross		$ 835,845	$ 866,306
Purchased Software [Member]
Property and Equipment, Useful Life (Year)		3 years
Property and Equipment, Gross		$ 320,435	320,435
Machinery and Equipment [Member]
Property and Equipment, Useful Life (Year)		5 years
Property and Equipment, Gross		$ 175,460	214,356
Other Machinery and Equipment [Member]
Property and Equipment, Gross		$ 311,973	304,492
Other Machinery and Equipment [Member] | Minimum [Member]
Property and Equipment, Useful Life (Year)		3 years
Other Machinery and Equipment [Member] | Maximum [Member]
Property and Equipment, Useful Life (Year)		5 years
Leasehold Improvements [Member]
Property and Equipment, Gross	[1]	$ 23,511	23,511
Furniture and Fixtures [Member]
Property and Equipment, Useful Life (Year)		7 years
Property and Equipment, Gross		$ 4,466	$ 3,512
[1]We amortize leasehold improvements over the term of the lease, which in all cases is shorter than the estimated useful life of the asset.

Note 9 - Accounts Payable, Ac_3

Note 9 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
UCSD [Member]
License Agreement Fees	$ 1,500,000
Account Payable [Member] | UCSD [Member]
License Agreement Fees	104,000
Accrued Liabilities and Other [Member] | UCSD [Member]
License Agreement Fees	1,400,000
Director Fees [Member] | Account Payable [Member]
Due to Related Parties, Current, Total	318,527	$ 57,099
Termination Costs, Bonuses, and Benefits [Member] | Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 811,554	$ 1,194,719

Note 9 - Accounts Payable, Ac_4

Note 9 - Accounts Payable, Accrued Liabilities and Other - Accrued Liabilities and Other (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Contracted services	$ 5,667,105	$ 1,913,756
Compensation	788,036	1,194,719
Other	1,621	0
Total accrued liabilities and other	$ 6,456,762	$ 3,108,515

Note 10 - Notes Payable (Detail

Note 10 - Notes Payable (Details Textual) - USD ($)					1 Months Ended			12 Months Ended
	Jul. 01, 2022	Apr. 10, 2022	Feb. 23, 2021	May 18, 2020	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2020	Dec. 31, 2022	Dec. 31, 2021
Difference Betweent Value of Conversion Stocks		$ 821,250
Interest Expense, Debt, Total								$ 344,024	$ 5,938
Notes Payable, Current, Total								543,613	453,427
Proceeds from Notes Payable, Total								2,500,000	0
Gain (Loss) on Extinguishment of Debt, Total								0	366,000
Long-Term Debt, Maturity, Year One								543,613
Long-Term Debt, Maturity, Year Two								2,500,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount						$ 565,760	$ 442,041
Debt Instrument, Interest Rate, Stated Percentage						4.36%	3.50%
Interest Expense, Debt, Total								4,126	5,938
Debt Instrument, Term						5 months	7 months
Debt Instrument, Periodic Payment, Total						$ 114,388	$ 63,888
Notes Payable, Current, Total									$ 453,427
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total				$ 366,000
Gain (Loss) on Extinguishment of Debt, Total			$ 366,000
Series E Preferred Stock Exchanged for Sereis F and G Preferred Stock [Member]
Conversion of Stock, Shares Converted		50,000
Series E Preferred Stock Exchanged for Sereis F Preferred Stock [Member]
Conversion of Stock, Shares Issued		1,740
Series E Preferred Stock Exchanged for Sereis G Preferred Stock [Member]
Conversion of Stock, Shares Issued		3,260
Bridge Loan [Member]
Debt Instrument, Face Amount		$ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total	$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage		8%
Debt Instrument, Unamortized Discount, Total		$ 835,876						628,285
Debt Issuance Costs, Net, Total		$ 14,626
Interest Expense, Debt, Total								334,592
Long-Term Debt, Total								2,500,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | AFCO Premium Credit LLC [Member]
Debt Instrument, Face Amount					$ 608,275
Debt Instrument, Interest Rate, Stated Percentage					7.85%
Interest Expense, Debt, Total								5,306
Long-Term Debt, Total								$ 543,613
Debt Instrument, Periodic Payment, Total					$ 69,967

Note 11 - Leases (Details Textu

Note 11 - Leases (Details Textual)	1 Months Ended	12 Months Ended
	Jun. 30, 2017 USD ($)	Dec. 31, 2022 USD ($) ft²	Dec. 31, 2021 USD ($)
Operating Lease, Payments		$ 291,111	$ 344,266
Selling, General and Administrative Expenses [Member]
Operating Lease, Expense		$ 123,309	$ 171,818
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property | ft²		5,000
Operating Lease, Monthly Base Rent		$ 3,012
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property | ft²		25,000
Operating Lease, Monthly Base Rent	$ 39,124	$ 28,149
Office Equipment [Member]
Operating Lease, Monthly Base Rent		136
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent		$ 287

Note 11 - Leases - Maturity of

Note 11 - Leases - Maturity of Lease Liabilities (Details)	Dec. 31, 2022 USD ($)
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 19,699
Lessee, Operating Lease, Liability, to be Paid, Year Two	1,355
Total undiscounted operating lease payments	21,054
Less imputed interest	766
Present value of operating lease liabilities	$ 20,288

Note 11 - Leases - Balance Shee

Note 11 - Leases - Balance Sheet Classification (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current lease liabilities	$ 18,976	$ 275,718
Noncurrent lease liabilities	1,312	$ 20,288
Present value of operating lease liabilities	20,288
Other Current Liabilities [Member]
Current lease liabilities	18,976
Other Noncurrent Liabilities [Member]
Noncurrent lease liabilities	$ 1,312

Note 11 - Leases - Other Inform

Note 11 - Leases - Other Information (Details)	Dec. 31, 2022
Weighted-average remaining lease term for operating leases (in years) (Year)	8 months 12 days
Weighted-average discount rate for operating leases	10.53%

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)

1 Months Ended

12 Months Ended

19 Months Ended

Jan. 30, 2023

Aug. 30, 2022

Dec. 09, 2021

Nov. 21, 2021

May 27, 2021

Mar. 16, 2021

Nov. 27, 2019

Apr. 09, 2018

Nov. 02, 2017

Mar. 03, 2017

Nov. 30, 2018

Jun. 30, 2016

Dec. 31, 2022

Mar. 31, 2022

Oct. 11, 2022

Jan. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Aug. 14, 2018

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ (8,143,310)

$ 624,743

$ 2,046,907

Common Stock [Member]

Stock Issued During Period, Shares, New Issues

70,500

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ 223,684

$ 221,277

$ 218,146

MT [Member]

Ownership Percentage

60%

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement

1,175,000

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow

250,000

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5%

CRG [Member]

Draws on Letter of Credit

$ 7,153,000

$ 7,100,000

CRG Loan Agreement, Texas Case [Member]

Litigation Settlement, Attorneys’ Fees

$ 2,800,000

Litigation Settlement, Amount Awarded to Other Party

$ 2,600,000

Loss Contingencies, Interest Rate

18%

Loss Contingency Accrual, Ending Balance

$ 3,385,429

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

$ 4,200,000

$ 4,100,000

Ohio Court of Common Pleas [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 4,300,000

Litigation Settlement, Reversal of Amount Awarded from Other Party

$ 4,300,000

Ohio Court of Common Pleas [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

$ 4,100,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

New York Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member]

Litigation Settlement, Amount Can Be Awarded to Other Party for Indemnification for Attorneys’ Fees

$ 14,955

Litigation Settlement, Amount Can Be Advanced to Other Party for Attorneys’ Fees Subject to Repayment

$ 1,237

Litigation Settlement, Advancement for Attorney's Fees and Disbursements

$ 143,172

New York Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member] | Subsequent Event [Member]

Litigation Settlement, Amount Awarded to Other Party

$ 12,600

Delaware Litigation Involving Former CEO and President [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 66,796

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

59,000,000

CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

66,000,000

CRG [Member] | Term Loan Agreement [Member] | Maximum [Member] | Ohio Court of Common Pleas [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

$ 66,000,000

Note 13 - Equity (Details Textu

Note 13 - Equity (Details Textual)												1 Months Ended	6 Months Ended	10 Months Ended	12 Months Ended			16 Months Ended
		Oct. 25, 2022 $ / shares shares	Sep. 09, 2022	Aug. 30, 2022 USD ($) $ / shares shares	Aug. 03, 2022 $ / shares shares	Jul. 01, 2022 USD ($)	Apr. 10, 2022 USD ($) shares	Apr. 07, 2022 shares	Jul. 08, 2021 USD ($) shares	Mar. 02, 2021 USD ($) $ / shares shares	Aug. 31, 2020 USD ($) shares	Nov. 30, 2018 shares	Dec. 31, 2021 USD ($) shares	Jul. 07, 2021 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 shares	Dec. 31, 2021 USD ($) shares	Aug. 31, 2022 shares	Jan. 31, 2022 USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance | $													$ 731,299		$ 292,518	$ 731,299		$ 731,299
Additional Paid in Capital, Total | $													$ 370,459,705		379,343,124	$ 370,459,705		$ 370,459,705
Stock Issued During Period, Value, New Issues | $															19,740
Operating Loss Carryforwards | $															$ 175,000,000
Share Purchase Right, Shares Issuable Per Each Right								0.001
Share Purchase Right, Ownership Percentage Threshold								4.99%
Share Purchase Right, Ownership Percentage Trigger								0.50%
Share Purchase Right, Discount Percentage								50%
Rights Offering, Shares Authorized				35,000	35,000
Shares Issued, Price Per Share | $ / shares				$ 1,000	$ 1,000
Units Issued During Period, Units, New Issues				10,423
Proceeds from Issuance or Sale of Equity, Total | $				$ 6,173,000
Units Issued During Period, Value, New Issues | $				10,423,000
Payments to Fund Clinical Research Trial | $				$ 998,401
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)															53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan | $															$ 44,720	$ 76,846
Stock Issued During Period, Value, Issued for Employee Bonuses | $															$ 24,847	$ 76,846
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	[1]														$ 0.54
Class of Warrant or Right, Outstanding															23,363,966
Common Stock, Capital Shares Reserved for Future Issuance															24,066,771
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 0.50
Warrants and Rights Outstanding, Term															6 months
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 49.80
Warrants and Rights Outstanding, Term															4 years 8 months 12 days
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 0.54
LTIP [Member]
Stock Issued During Period, Shares, New Issues															70,500
Stock Issued During Period, Value, New Issues | $															$ 19,740
Incentive Plan, Milestone, Percent, Step of Total Stock Award Payout			5%
Incentive Plan, Milestone, Percent, Regulatory Milestones			90%
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage			100%
Incentive Plan, Percent, Milestones Paid															5%
Common Stock [Member]
Stock Issued During Period, Shares, New Issues															70,500
Stock Issued During Period, Value, New Issues | $															$ 71
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)															53,238
Stock Issued During Period, Value, Employee Benefit Plan | $															$ 53
Stock Issued During Period, Shares, Issued for Employee Bonuses															44,782	30,018
Stock Issued During Period, Value, Issued for Employee Bonuses | $															$ 45	$ 30
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses															44,782
Stock Issued During Period, Value, Issued for Employee Bonuses | $															$ 24,847
John K. Scott, Jr. [Member]
Maximum Number of Units Purchasable				2,400
Director [Member]
Common Stock, Capital Shares Reserved for Future Issuance															102,869
Former Chief Executive Officer and President [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues												925,000
Stock Issued During Period, Shares, New Issues Placed in Escrow												250,000			250,000
Unit Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				2,222
Class of Warrant or Right, Purchase Price of Stock | $ / shares				$ 0.45
Class of Warrants or Rights, Warrant Proceeds if Exercised | $				$ 11,600,000
Warrants and Rights Outstanding | $				$ 4,144,185
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.50
Unit Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				0.8925
Unit Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0.0327
Unit Warrants [Member] | Measurement Input, Expected Dividend Payment [Member]
Warrants and Rights Outstanding, Measurement Input				0
Series LL Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															62,361
Class of Warrant or Right, Exercises in Period		218,264
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.20
Stock Issued During Period Shares Stock Warrants Exercised		62,361
Bridge Loan [Member]
Debt Instrument, Face Amount | $							$ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total | $						$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage							8%
Conversion from Series D Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted																54,750	17,750	72,500
Conversion of Stock, Shares Issued																2,951,509	827,280	3,778,789
Common Stock, Capital Shares Reserved for Future Issuance															21,064,560
Series E Preferred Stock Exchanged for Sereis F and G Preferred Stock [Member]
Conversion of Stock, Shares Converted							50,000
Series E Preferred Stock Exchanged for Sereis F Preferred Stock [Member]
Conversion of Stock, Shares Issued							1,740
Series E Preferred Stock Exchanged for Sereis G Preferred Stock [Member]
Conversion of Stock, Shares Issued							3,260
Units Sold in Exchange for Series D Preferred Stock [Member]
Units Issued During Period, Units, New Issues				4,250
Convertible Preferred Stock, Fair Value | $															$ 2,212,114
Convertible Preferred Stock, Shares Issued Upon Conversion, Fair Value | $															4,250,000
Dividends, Preferred Stock, Total | $															$ 2,037,886
MT Preferred Stock [Member]
Additional Paid in Capital, Total | $																				$ 438,778
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues | $																$ 2,550,001
Preferred Stock, Shares Outstanding, Ending Balance													22,077		0	22,077		22,077
Series D Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues																0
Stock Issued During Period, Value, New Issues | $																$ 0
Series D Preferred Stock [Member] | Keystone Capital Partners, LLC [Member]
Stock Issued During Period, Shares, New Issues									22,077		150,000		77,500	72,500		76,827
Stock Issued During Period, Value, Other | $											$ 15,000,000
Convertible Preferred Stock, Discount to Market Rate											10%
Convertible Preferred Stock, Maximum Allowed Percentage of Common Stock Outstanding Used in Conversion Shares											19.99%
Convertible Preferred Stock, Shares Issued upon Conversion																			5,147,000
Stock Issued During Period, Value, New Issues | $									$ 2,200,000					$ 7,250,000		$ 7,700,000
Preferred Stock, Shares Outstanding, Ending Balance													22,077		0	22,077		22,077
Series E Preferred Stock [Member]
Stock Issued During Period, Value, New Issues | $																$ 4,930,038
Preferred Stock, Shares Outstanding, Ending Balance													50,000		0	50,000		50,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares										$ 2.30
Preferred Stock, Redemption Price Per Share | $ / shares										$ 110
Series E Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues																0
Stock Issued During Period, Value, New Issues | $																$ 0
Series E Preferred Stock [Member] | John K. Scott, Jr. [Member]
Stock Issued During Period, Shares, New Issues										50,000
Stock Issued During Period, Value, New Issues | $										$ 5,000,000
Percentage of Securities Allowed to be Purchased in Third-Party Offering, Maximum										33.33%
Series I Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion				2,222
Stock Issued During Period, Value, New Issues | $				$ 6,278,815											$ 5,174,599
Preferred Stock, Shares Outstanding, Ending Balance													0		9,480	0		0
Series I Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues															0
Stock Issued During Period, Value, New Issues | $															$ 0
MT [Member]
Ownership Percentage																				60%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance | $																				$ 731,299
[1]Weighted average exercise price.

Note 13 - Equity - Outstanding

Note 13 - Equity - Outstanding Warrants (Details)	Dec. 31, 2022 $ / shares shares
Exercise price (in dollars per share) | $ / shares	$ 0.54	[1]
Number of warrants (in shares) | shares	23,363,966
Series HH Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 49.80
Number of warrants (in shares) | shares	15,060
Series OO Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 0.9375
Number of warrants (in shares) | shares	189,000
Series PP Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 0.50
Number of warrants (in shares) | shares	23,159,906
[1]Weighted average exercise price.

Note 14- Income Taxes (Details

Note 14- Income Taxes (Details Textual) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets, Tax Credit Carryforwards, Research and Development	[1]	$ 9,256,968	$ 9,501,299
Operating Loss Carryforwards		175,000,000
Domestic Tax Authority [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research and Development		8,868,343
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards		175,127,244	168,776,440
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount Expired During Period		5,350	0
State and Local Jurisdiction [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research and Development		388,625
Operating Loss Carryforwards		$ 20,068,842	$ 20,068,842
[1]Includes U.S. R&D credit carryforwards of $8,868,343 and state R&D credit carryforwards of $388,625 as of December 31, 2022.

Note 14 - Income Taxes - Compon

Note 14 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)		Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards		$ 39,200,586	$ 36,793,074
R&D credit carryforwards	[1]	9,256,968	9,501,299
Stock compensation		286,724	481,098
Intangibles		455,959	567,213
Accrued expenses		710,940	0
Capitalized §174 expenses		1,116,433	0
Disallowed interest expense		0	851,247
Temporary differences		196,575	305,974
Deferred tax assets before valuation allowance		51,224,185	48,499,905
Valuation allowance		(51,224,185)	(48,499,905)
Net deferred tax assets		$ 0	$ 0
[1]Includes U.S. R&D credit carryforwards of $8,868,343 and state R&D credit carryforwards of $388,625 as of December 31, 2022.

Note 14 - Income Taxes - Net Op

Note 14 - Income Taxes - Net Operating Loss and Credit Carryforwards (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
U.S. Net Operating Loss Carryforwards	$ 175,000,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	175,127,244	$ 168,776,440
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2012 [Member]
U.S. Net Operating Loss Carryforwards	18,898,490
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2013 [Member]
U.S. Net Operating Loss Carryforwards	37,450,522
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2014 [Member]
U.S. Net Operating Loss Carryforwards	34,088,874
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2015 [Member]
U.S. Net Operating Loss Carryforwards	25,073,846
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2016 [Member]
U.S. Net Operating Loss Carryforwards	15,581,209
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2019 [Member]
U.S. Net Operating Loss Carryforwards	11,245,808
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2020 [Member]
U.S. Net Operating Loss Carryforwards	11,018,478
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2021 [Member]
U.S. Net Operating Loss Carryforwards	15,419,213
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Tax Year 2022 [Member]
U.S. Net Operating Loss Carryforwards	6,350,804
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	8,868,343
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2003 [Member]
U.S. R&D Credit Carryforwards	2,905
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2004 [Member]
U.S. R&D Credit Carryforwards	22,861
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2005 [Member]
U.S. R&D Credit Carryforwards	218,332
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2006 [Member]
U.S. R&D Credit Carryforwards	365,541
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2007 [Member]
U.S. R&D Credit Carryforwards	342,898
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2008 [Member]
U.S. R&D Credit Carryforwards	531,539
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2009 [Member]
U.S. R&D Credit Carryforwards	596,843
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2010 [Member]
U.S. R&D Credit Carryforwards	1,094,449
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2011 [Member]
U.S. R&D Credit Carryforwards	1,950,744
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2012 [Member]
U.S. R&D Credit Carryforwards	468,008
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2013 [Member]
U.S. R&D Credit Carryforwards	681,772
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2014 [Member]
U.S. R&D Credit Carryforwards	816,116
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2015 [Member]
U.S. R&D Credit Carryforwards	492,732
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2016 [Member]
U.S. R&D Credit Carryforwards	262,257
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2017 [Member]
U.S. R&D Credit Carryforwards	387,892
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2018 [Member]
U.S. R&D Credit Carryforwards	197,547
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2019 [Member]
U.S. R&D Credit Carryforwards	213,065
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member] | Tax Year 2020 [Member]
U.S. R&D Credit Carryforwards	$ 222,842

Note 14 - Income Taxes - Reconc

Note 14 - Income Taxes - Reconciliations Between the Statutory Federal Income Tax Rate and the Effective Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Benefit at statutory rate, amount	$ (3,137,533)	$ (2,460,126)
Benefit at statutory rate, percent	(21.00%)	(21.00%)
Adjustments to valuation allowance, amount	$ 2,724,281	$ 2,676,868
Adjustments to valuation allowance, percent	17.90%	22.90%
Adjustments to R&D credit carryforwards, amount	$ 0	$ (199,589)
Adjustments to R&D credit carryforwards, percent	0%	(1.70%)
Permanent items and other, amount	$ 413,252	$ (1,110)
Permanent items and other, percent	3.10%	(0.10%)
Provision (benefit) per financial statements, amount	$ 0	$ 16,043

Note 15 - Segments (Details Tex

Note 15 - Segments (Details Textual)		12 Months Ended
		Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Revenues, Total		$ 65,652	$ 531,513
Number of Primary Types of Products Sold		2
Depreciation and amortization (2)	[1]	$ 95,819	76,954
Selling, General and Administrative Expenses [Member]
Depreciation and amortization (2)		95,819	$ 76,954
Intersegment Eliminations [Member]
Revenues, Total		$ 0
[1]Depreciation and amortization are reflected in selling, general and administrative expenses ($95,819 and $76,954 for the years ended December 31, 2022 and 2021, respectively).

Note 15 - Segments - Segment In

Note 15 - Segments - Segment Information (Details) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax		$ 14,645	$ 45,615
Grant and other revenue		51,007	485,898
Revenues, Total		65,652	531,513
Research and development expenses		5,969,774	5,141,910
Cost of revenue		1,941	0
Selling, general and administrative expenses, excluding depreciation and amortization (1)	[1]	7,866,007	7,373,061
Adjustments for expired and expiring inventory		183,006	0
Depreciation and amortization (2)	[2]	95,819	76,954
Loss from operations (3)	[3]	(14,050,895)	(12,060,412)
Other expense, net (4)	[4]	(1,126,261)	345,524
Provision for income taxes		0	(16,043)
Net loss		(15,177,156)	(11,730,931)
United States		4,371,606	6,644,833
Capital expenditures		63,086	25,218
UNITED STATES
United States		3,817,805	6,433,962
Non-US [Member]
United States		553,801	210,871
Diagnostics Segment [Member]
Grant and other revenue		51,007	485,898
Revenues, Total		65,652	531,513
Research and development expenses		5,501,134	4,488,177
Cost of revenue		1,941
Selling, general and administrative expenses, excluding depreciation and amortization (1)	[1]	0	0
Adjustments for expired and expiring inventory		183,006
Depreciation and amortization (2)	[2]	29,387	24,162
Loss from operations (3)	[3]	(5,649,816)	(3,980,826)
Other expense, net (4)	[4]	0	0
Provision for income taxes			(5,452)
Net loss		(5,649,816)	(3,986,278)
Capital expenditures		54,650	0
Diagnostics Segment [Member] | UNITED STATES
United States		610	107,931
Diagnostics Segment [Member] | Non-US [Member]
United States		539,188	210,281
Therapeutics Segment [Member]
Grant and other revenue		0	0
Revenues, Total		0	0
Research and development expenses		468,640	653,733
Cost of revenue		0
Selling, general and administrative expenses, excluding depreciation and amortization (1)	[1]	4,530	4,438
Adjustments for expired and expiring inventory		0
Depreciation and amortization (2)	[2]	0	0
Loss from operations (3)	[3]	(473,170)	(658,171)
Other expense, net (4)	[4]	0	0
Provision for income taxes			(901)
Net loss		(473,170)	(659,072)
Capital expenditures		0	0
Therapeutics Segment [Member] | UNITED STATES
United States		0	0
Therapeutics Segment [Member] | Non-US [Member]
United States		0	0
Corporate Segment [Member]
Grant and other revenue		0	0
Revenues, Total		0	0
Research and development expenses		0	0
Cost of revenue		0
Selling, general and administrative expenses, excluding depreciation and amortization (1)	[1]	7,861,477	7,368,623
Adjustments for expired and expiring inventory		0
Depreciation and amortization (2)	[2]	66,432	52,792
Loss from operations (3)	[3]	(7,927,909)	(7,421,415)
Other expense, net (4)	[4]	(1,126,261)	345,524
Provision for income taxes			(9,690)
Net loss		(9,054,170)	(7,085,581)
Capital expenditures		8,436	25,218
Corporate Segment [Member] | UNITED STATES
United States		3,817,195	6,326,031
Corporate Segment [Member] | Non-US [Member]
United States		14,613	590
Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax		14,645	0
Royalty [Member] | Diagnostics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax			0
Royalty [Member] | Therapeutics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax			0
Royalty [Member] | Corporate Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax			0
Sales Revenue [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0
Sales Revenue [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		14,645
Sales Revenue [Member] | Diagnostics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax		14,645	0
Sales Revenue [Member] | Diagnostics Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0
Sales Revenue [Member] | Diagnostics Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		14,645
Sales Revenue [Member] | Therapeutics Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0
Sales Revenue [Member] | Therapeutics Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		0
Sales Revenue [Member] | Corporate Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0
Sales Revenue [Member] | Corporate Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		0
License [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 0	45,615
License [Member] | Diagnostics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax			45,615
License [Member] | Therapeutics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax			0
License [Member] | Corporate Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax			$ 0
[1]General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.[2]Depreciation and amortization are reflected in selling, general and administrative expenses ($95,819 and $76,954 for the years ended December 31, 2022 and 2021, respectively).[3]Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.[4]Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 16 - Material Agreements (

Note 16 - Material Agreements (Details Textual) - USD ($)				1 Months Ended	12 Months Ended		15 Months Ended
	Oct. 24, 2022	Nov. 23, 2021	Jul. 14, 2014	Jan. 31, 2002	Dec. 31, 2022	Dec. 31, 2021	Oct. 24, 2021
Research and development expenses					$ 5,969,774	$ 5,141,910
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number					537,390
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period					35,000	70,000
Former Chief Executive Officer [Member]
Employment Agreement, Annual Base Salary							$ 490,000
Separation Agreement, Salary Continuation		$ 490,000
Separation Agreement, Salary Continuation, Term	10 months	12 months
Separation Agreement, Salary Continuation, Percentage of Base Salary	50%	100%
Separation Agreement, Reimbursement for Attorney Fees		$ 24,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number		69,918
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number		333,332
Separation Agreement, Reimbursed Expenses, Per Hour		250
Former Chief Executive Officer [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period		33,333
Tc99m Tilmanocept License Agreement [Member]
License Issue Fee				$ 25,000
License Maintenance Fee				25,000
Minimum Annual Royalty				$ 25,000
Expanded Tc99m Tilmanocept License Agreement [Member] | License [Member]
Research and development expenses					$ 101,409	$ 20,702
Expanded Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | License [Member]
Cost of Goods and Services Sold, Total					868	4,339
Amended and Restated Tilmanocept License Agreement [Member]
License Issue Fee			$ 25,000
License Maintenance Fee			25,000
Minimum Annual Royalty			$ 25,000
Research and development expenses					$ 25,000	$ 25,000

Note 17 - Employee Benefit Pl_2

Note 17 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6%
Defined Contribution Plan, Cost	$ 30,755	$ 148,406

Note 18 - Supplemental Disclo_2

Note 18 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)		12 Months Ended
	Aug. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2020
Interest Paid, Excluding Capitalized Interest, Operating Activities		$ 136,432	$ 9,015
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)		53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan		$ 44,720	$ 76,846
Stock Issued During Period, Value, Issued for Employee Bonuses		24,847	$ 76,846
Stock Issued During Period, Value, New Issues		19,740
Stock Issued During Period, Value, Exchange of Securities		$ 821,250
Conversion from Series I Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted		943
Conversion of Stock, Shares Issued		2,095,490
Series I Preferred Stock [Member]
Stock Issued During Period, Value, New Issues	$ 6,278,815	$ 5,174,599
Preferred Stock, Deemed Dividend		$ 2,037,886
Series LL Warrants [Member]
Class of Warrant or Right, Exercised During Period		218,264
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		62,361
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | AFCO Premium Credit LLC [Member]
Debt Instrument, Face Amount				$ 608,275
Debt Instrument, Interest Rate, Stated Percentage				7.85%
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount					$ 565,760	$ 442,041
Debt Instrument, Interest Rate, Stated Percentage					4.36%	3.50%
LTIP [Member]
Stock Issued During Period, Shares, New Issues		70,500
Stock Issued During Period, Value, New Issues		$ 19,740
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)		53,238
Stock Issued During Period, Value, Employee Benefit Plan		$ 53
Stock Issued During Period, Shares, Issued for Employee Bonuses		44,782	30,018
Stock Issued During Period, Value, Issued for Employee Bonuses		$ 45	$ 30
Stock Issued During Period, Shares, New Issues		70,500
Stock Issued During Period, Value, New Issues		$ 71
Common Stock [Member] | Series I Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues		0
Stock Issued During Period, Value, New Issues		$ 0
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses		44,782
Stock Issued During Period, Value, Issued for Employee Bonuses		$ 24,847

Note 19 - Subsequent Events (De

Note 19 - Subsequent Events (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Amended and Restated Tilmanocept License Agreement [Member] | Forecast [Member]
Increase (Decrease) in Accrued Liabilities, Total	$ 1.2